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Aim: Although nasal drug delivery is gaining increasing interest over the last two 
decades, there is no well validated and readily accessible in vitro biological model 
that is suitable for rapid screening for nasal drug delivery. Thus, the present study 
aims to (1) develop and validate a cell line model (Calu-3 cell line) as an in vitro 
model for nasal drug permeation screening; (2) investigate the permeation of 
selected drug candidates using this model, leading to identification of a most 
promising drug candidate. 
Methods and Results: To develop the Calu-3 cell line model, the cells were 
seeded on the Transwell® inserts at a density of 2x10^ cells/well and cultured under 
an air-interfaced condition. The integrity of the Calu-3 cell monolayers was 
verified by monitoring the transepithelial electrical resistance (TEER) and 
permeabilities of tritiated water as well as various transcelluar and paracellular 
markers. The effect of osmolarity on the Calu-3 cell monolayer was also studied. 
Inter-passage variation was examined by measuring the permeabilities of the 
paracellular maker [i4c]-Mannitol and transcellular marker [^H]-Dexamethasone 
across the Calu-3 cell monolayers between passage 21 to 25. The apparent 
permeability coefficients (Papp) of the marker compounds ranged from 1.14 ±0.11 
xl0-7cm/s to 398.07 ±57 .62 x i O ' W s , with Papp of paracellular markers < 
transcellular markers < tritiated water as expected. Hypoosmotic solutions not only 
significantly decreased the TEER of the Calu-3 cell monolayers but also 
XV 
significantly enhanced the permeability of the paracellular marker [^"^CJ-Mannitol 
but not the transcellular marker [^H]-Dexamethasone. No significant inter-passage 
variation was found within the passage number range 21 to 25. The optimal 
condition for Calu-3 cell monolayers for the permeation studies appeared to be 
between 15 and 21 days of culture based on TEER greater than 500 Q-cm . 
To investigate the ability of Calu-3 cell line for nasal drug screening, four 
selected drug candidates (i.e. rizatriptan, meloxicam, lomoxicam and nebivolol) 
with potential therapeutic advantage of nasal delivery were investigated using the 
Calu-3 cell line model. The permeability of each drug candidate was determined 
and the factors (including concentration, pH and osmolarity) that may affect their 
permeabilities in the Calu-3 cell line model were also evaluated. In addition, to 
further validate the Calu-3 cell line model, permeation studies of these drug 
candidates at different pHs were compared between the artificial membrane model 
and the Calu-3 cell line model. It was found that passive diffusion was the main 
transport pathway for rizatriptan, meloxicam and lomoxicam in permeating 
through the Calu-3 cell line model and their permeabilities were also pH dependent. 
Nebivolol was highly lipophilic, which led to a very low solubility and an 
extraordinarily high cellular uptake in the Calu-3 cell monolayers. Such high 
cellular uptake of nebivolol resulted in a low permeability and high toxicity in the 
Calu-3 cell monolayers. Therefore, nebivolol was given up and no further 
investigation of it was carried out in the Calu-3 cell line model. Hypoosmolarity 
enhanced the permeability of the drug candidate (rizatriptan) that permeates mainly 
through the paracellular pathway. A correlation was observed for the permeabilities 
of studied drug candidates under different pHs between the two models. 
vi 
Based on the results of in vitro permeation studies using the Calu-3 cell line 
model, the reported pharmacokinetics data, and the stability data, meloxicam was 
predicted as the most promising drug candidate to achieve rapid and significant 
absorption in vivo and thus its nasal absorption studies were carried out in rats. The 
pharmacokinetics of meloxicam was determined at a dose of 1 mg/kg through the 
nasal route and compared with that obtained through intravenous and oral routes. 
Plasma samples were obtained at different time intervals after drug administration 
followed by liquid-liquid extraction. The treated samples were analyzed by a 
developed and validated HPLC-UV assay method. When comparing the 
pharmacokinetics parameters obtained, it was found that nasal administration of 
meloxicam was comparable with its intravenous administration, with respect to 
plasma drug concentration and AUCo-2h. In addition, nasal absorption of 
meloxicam was much more rapid with higher plasma drug concentration and 
AUCo.2h than that of oral administration. A preliminary estimation of the in vitro -
in vivo correlation of the Calu-3 cell line model versus the animal models based on 
data from the current study and the published ones indicated that the Calu-3 cell 
line model can appropriately predict the in vivo nasal absorption. 
Conclusion: The results of the present work indicate that the Calu-3 cell line 
model appears to be a useful in vitro biological model for screening of the drug 
candidates for nasal delivery. Identification of potential compound (meloxicam) for 
nasal drug delivery via screening confirmed a rapid absorption of the drug as well 
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The most desirable and commonly used route of drug administration is the 
oral route due to its convenience and compatibility. However, not all drugs are 
suitable for oral administration (Davis et al.，2003) due to the following reasons: 1) 
some drugs may be degraded by the enzymes in the gastrointestinal tract, which 
would result in very low bioavailability and failure to achieve systemic effect; 2) 
some drugs are so extensively metabolized by the liver that only a small amount of 
unchanged drugs can enter the systemic circulation; 3) some drugs are irritative to 
the GI mucosa and may induce GI disorder; 4) a relatively slow onset of action for 
the orally administered drugs may not be suitable for occasion of emergency. 
Conventionally, parenteral routes such as the intravenous, intramuscular and 
subcutaneous injections are employed to avoid the above-mentioned problems. The 
disadvantages of the injections are obvious: they are invasive, inconvenient and 
more expensive. Therefore, over the last few decades, scientists have been trying to 
explore other possibilities such as buccal, ocular, sublingual, rectal, vaginal, 
pulmonary and nasal drug delivery. The buccal and ocular mucosae are usually 
poorly permeable and the drug absorption can be slow (Rojanasakul et al., 1992). 
Sublingual mucosa is very permeable, but some research indicated that the 
sublingual delivery method may lack a standardized technique (Oliver, 1994). 
Rectal and vaginal administrations are not well accepted due to their inconvenience. 
Pulmonary drug delivery is often limited by the irritant nature of certain 
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compounds and ineffectiveness to reach the alveolar region (Davis et al., 2003). 
Among all the alternative drug administration sites, nasal mucosa is relatively 
highly permeable (Rojanasakul et al., 1992; Corbo et a l , 1990), and nasal drug 
administration is convenient and well accepted. The detailed information of nasal 
drug delivery will be introduced below. 
1.1 Overview of nasal drug delivery 
The nasal route is currently being utilized or investigated for the following 
purposes: 
1) Local delivery for treatment of rhinitis or nasal cold symptoms (Costantino 
et al., 2007). 
2) Vaccine delivery: Since the nasal-associated lymphoid tissue is reported to 
be a mucosal inductive site for humoral and cellular immune responses in the upper 
respiratory tract (Zuercher et al., 2002), the nasal mucosa has received some 
interest as a route for vaccination. An example of nasal vaccine is FluMist®, an 
influenza virus vaccine. Several other nasal vaccines are also reported to be under 
investigation in human subjects (Costantino et al., 2007). 
3) CNS delivery: A number of studies have reported that a drug may be 
transported directly into the brain tissue or the cerebrospinal fluid (CSF) by 
transport across the olfactory region of the nasal cavity (Ilium, 2004; Vyas et al., 
2005). However, it should be noticed that there are also a few cases where no 
evidence was found for direct nose-CSF transport (van den Berg et a l , 2004 a,b). 
4) Systemic delivery: Drug delivery via the nasal route for systemic delivery 
purpose is gaining increasing interest over the last two decades as an alternative to 
oral and parenteral drug administrations. Nasal drug delivery can bypass the 
Chapter One 
gastrointestinal and hepatic first-pass metabolisms following oral administration 
and therefore result in higher bioavailability. In addition, nasal mucosa is more 
permeable than many other mucosae (Rojanasakul et al., 1992; Corbo et al.，1990) 
and is highly vascularized (Ugwoke et al., 2001), which can lead to rapid 
absorption and thus quick onset of action. Moreover, comparing with the parenteral 
routes of administration, nasal drug delivery is much more convenient and 
acceptable for patients. 
To better understand the basis for nasal drug absorption, a brief description of 
the nasal anatomical structure and the relevant permeability is necessary. 
1.1.1 Structure and permeability of the nasal mucosa 
The nasal cavity is divided into two halves by the nasal septum and can be 
segregated into 5 anatomical regions (Ugwoke et al., 2005), namely, nasal vestibule, 
atrium, respiratory region, olfactory region and nasopharynx (Figure 1.1). The 
structural features of these regions are responsible for their specific permeability 
towards chemicals or drugs. 
The epithelial cells in the nasal vestibule, which opens to the outside 
environment, are stratified, squamous and keratinized with sebaceous glands. The 
nasal vestibule is very resistant to environmental substances due to the presence of 
keratinized cells that could initiate the self-protective function of the nasal 
vestibule (Ugwoke et al., 2005). Therefore, the permeation of drugs is usually poor 
in this region. 
The atrium is a transitional epithelial region with stratified, squamous cells 
anteriorly and pseudostatified columnar cells with microvilli posteriorly (Ugwoke 
et al., 2005). It is not very permeable due to the small surface area and the stratified 
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cells present in the front part (Arora et al., 2002). 
Figure 1.1 Schematic of a sagittal section of human nasal cavity showing the 
nasal vestibule (A), atrium (B), respiratory region: inferior turbinate (CI), middle 
turbinate (C2) and the superior turbinate (C3), the olfactory region (D) and 
nasopharynx (E). (Ugwoke et al.，2005) 
The respiratory region occupies the major part of the nasal cavity. It possesses 
lateral walls that divide it into three sections, including inferior turbinate, middle 
turbinate and superior turbinate. These folds provide the nasal cavity with a very 
high surface area compared with its small volume and are mainly responsible for 
heating and humidification of the air inhaled (Ugwoke et al., 2005). The respiratory 
region is covered by typical airway epithelium, which is ciliated, pseudostratified 
and columnar. As shown in Figure 1.2, the nasal epithelium of the respiratory 
region comprises four major cell types: ciliated and no-ciliated columnar cells, 
basal cells and goblet cells (Mygind et al., 1998). Each ciliated cell possesses about 
100 cilia, while all columnar cells, ciliated and non-ciliated, are covered by about 
300 microvilli (Mygind et a l , 1998; Ugwoke et al., 2005). The existence of cilia 
and microvilli largely increases the surface area of the respiratory region and makes 
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it the most permeable region of the nasal cavity. In addition, this region is rich in 
blood vessels, which ensures that the drugs permeated can quickly enter the 
systemic circulation to demonstrate their therapeutic effects (Ugwoke et al., 2005). 
Therefore, the respiratory region is the most suitable region for nasal drug 
administration for systemic action. 
_ 
F 0 
Figure 1.2 Cell types of the nasal epithelium showing ciliated cell (A), 
non-ciliated cell (B), goblet cell (C), gel mucus layer (D), sol layer (E), basal cell 
(F) and basement membrane (G). (Ugwoke et al., 2005) 
The olfactory epithelium is a modified respiratory epithelium which is also 
pseudostratified with a total surface area of 200-400 square millimeters (Ugwoke et 
al., 2001). It comprises olfactory sensory neurons, supporting cells and basal cells 
(Ilium, 2004). The olfactory epithelium is unique in the central nervous system 
(CNS), since it is the only part in direct contact with the environment (Ilium, 2004). 
Hence drugs may circumvent the blood-brain barrier and be absorbed directly into 
the CNS after nasal administration. 
The upper part of the nasopharynx is covered by a ciliated epithelium and the 
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lower part of it is covered by a squamous epithelium. The nasopharynx receives 
nasal cavity drainage (Arora et al., 2002). 
1.1.2 Pathways of drug permeation across nasal mucosa 
Studies showed that there are generally two drug transport pathways, namely, 
paracellular and transcellular transport pathways. Paracellular transport is usually a 
passive diffusion process between epithelial cells which are closely connected by 
intercellular junctions. Transcellular transport can be either passive or active, and 
the latter could be carrier-mediated transport or pinocytosis (Schmidt et al., 1998). 
Since paracellular surface area is much smaller than the transcellular surface area, 
the paracellular permeability is much lower than the transcellular permeability. 
Transport of chemicals across nasal mucosa can be mediated by one or a 
combination of several ways mentioned above. Most compounds can permeate 
across the nasal mucosa through both paracellular and transcellular pathways 
simultaneously, and the dominant transport pathway will be determined mainly by 
the lipophilicity of the compound (Arora et al., 2002). Hydrophilic compounds 
usually permeate via the paracellular pathway, while lipophilic compounds are 
more likely to permeate transcellularly. 
According to Pick's first law of diffusion, the apparent permeability 
coefficient (Papp) can be calculated according to the following equation: 
Papp=(dQ/dt)/(A.Co) 
Where dQ/dt (mol/sec) is the steady-state rate of change in cumulative mass 
permeated, A (cm^) is the surface area for permeation, and Co (mol/ml) is the initial 
dosing concentration in the donor chamber. 
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1.1.3 Models for nasal drug permeation studies 
In order to investigate the drug permeation/absorption through the nasal route, 
various in vitro, in situ and in vivo animal models have been employed for 
preclinical screening purposes. 
1.1.3.1 In vitro models 
The advantage of in vitro model is largely due to its ability to control variables 
and separation of the absorption process from the subsequent distribution and 
elimination process in vivo. For nasal drug permeation/absorption studies, artificial 
membrane, primary cell culture, nasal tissues and cell lines are generally used. 
1.1.3.1.1 Artificial membrane 
Artificial membrane model is an in vitro non-biological model that has been 
used to mimic and predict drug permeation through a number of biological barriers, 
such as intestinal membrane, blood-brain barrier, and skin (Santi et al., 1991; Zhu 
et al., 2002; Sugano et al., 2002; Di et al., 2003; Carrara et al” 2007). 
Artificial membrane model is a filter-supported lipid membrane system. 
Various materials have been utilized as the supporting filter or the lipid membrane. 
Polyvinylidene fluoride, polycarbonate, polypropylene and cellophane have been 
commonly used as the supporting filter (Santi et al., 1991; Wohnsland et al., 2001; 
Sugano et al., 2001 a,b; Kerns et al., 2004). Phosphatidyl choline, hexadecane, 
isopropyl myristate, and a complex system containing phosphatidylcholine (0.8%) / 
phosphatidylethanolamine (0.8%) / phosphatidylserine (0.2%) / 
phosphatidylinositol (0.2%) / cholesterol (1.0%) / 1,7-octadiene (97.0%), have 
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been utilized as the lipid membrane (Santi et al., 1991; Wohnsland et al., 2001; 
Sugano et al., 2001 a,b; Zhu et al., 2002). At present, permeation studies in the 
artificial membrane model are usually carried out in the form of parallel artificial 
membrane permeability assay (PAMPA), which was first introduced by Kansy et al. 
(1998) as a high throughput screening approach based on 96-well plate technology 
to measure artificial membrane permeability and to assess drug absorption 
potential. 
The predictability of the artificial membrane has been examined by comparing 
the permeability coefficients ( P a p p ) of a series of drugs obtained in the artificial 
membrane model with that obtained in the cell line models or in vivo. Comparisons 
between the artificial membrane model and the Caco-2 or MDRl-MDCKII cell line 
model, which are the most widely used and promising cell lines for in vitro 
evaluation of intestinal and brain permeation of drugs respectively, have been 
conducted (Zhu et al” 2002; Kerns et al., 2004; Carrara et al., 2007). It was found 
that for the drugs that permeate mainly through passive diffusion, permeability 
results obtained from artificial membrane model was comparable to that from 
Caco-2 and MDRl-MDCKII cell line models. In addition, the permeabilities of 
various drugs through the artificial membrane model were also reported to be 
comparable to that obtained from in vivo absorptions through rat blood-brain 
barrier (Di et al., 2003) and human intestine (Zhu et al., 2002), and thus the 
artificial membrane model was considered to be able to predict passive blood-brain 
barrier or intestinal absorption with high success. 
It should be noted that the artificial membrane model can only predict the 
permeation of drugs that are mainly absorbed through transcellular passive 
diffusion, and it may have limitation in predicting paracellular or active transport 
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(Kansy et al., 1998; Kems et al., 2004). Therefore, the permeation of small 
hydrophilic compounds would be underestimated. According to Adson et al. (1994), 
the paracellular permeation could be predicted using the calculation model for 
molecular size-restricted diffusion within a negative electrostatic field of force. The 
Renkin function was employed as the molecular size-restriction function in their 
model. Thus, Sugano et al. (2002，2003) tried to improve the artificial membrane 
model by combining the artificial membrane model with the paracellular pathway 
prediction model based on Renkin function. Comparison of this modified artificial 
membrane model with human intestine (Sugano et al., 2002) and human jejunum 
segment (Sugano et al., 2003) demonstrated its capability to predict the overall 
transcellular and paracellular passive permeability of a drug adequately. 
1.1.3.1.2 Primary cell culture 
Human primary nasal epithelial cells are usually obtained from patients 
undergoing nasal surgery (Werner et al., 1995; Yoo et al., 2003). Sometimes, the 
cells may also come from nasal scrapings of healthy volunteers (Lopez-Souza et al., 
2003). Since the nasal cavity can be divided into several divisions and each 
division has different function and constitution, the origins of samples can largely 
affect the characteristics of the primary cell culture model (Schmidt et al., 1998). 
As reviewed above, the respiratory region is the optimal region for nasal drug 
absorption. Therefore, the samples for primary cell culture are usually obtained 
from this region. 
A number of studies have reported that human primary nasal epithelial cells 
could be cultured into differentiated epithelial cell monolayers that contain ciliated 
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nasal cells and mucus producing goblet cells with tight junction (Werner et a l , 
1995; Werner et al. 1996; Yoo et al.，2003; Lopez-Souza et al., 2003; Lee et al., 
2005). However, the main limitation of this model is its limited access and short 
lifespan. The nasal primary cells can only be subcultured 3 or 4 passages at most 
without morphological deviation, which makes the long-term reproducibility 
difficult (Yoo et al., 2003; Lee et al., 2005). In addition, it is very difficult to isolate 
the epithelial cells from the other cells, such as fibroblasts, endothelial cells and 
myoblasts, in the sampled tissue (Schmidt et al., 1998). Moreover, the culture 
condition required for human primary nasal epithelial cells is also very complicated, 
with various special compositions in the culture medium, such as transferrin, 
triiodothyronine, insulin and epidermal growth factor (Schmidt et al., 1998; Yoo et 
al.，2003). 
1.1.3.1.3 Nasal tissue 
Excised nasal tissue 
Excised nasal mucosae from a number of animals, such as pigs, rabbits, cattle 
and sheep, have been used to study nasal permeability of drugs (Reardon et al., 
1993; Kubo et al., 1994; Wadell et al” 1999; Schmidt et al., 2000). According to 
Schmidt et al. (2000), the bovine nasal mucosa resembles the typical respiratory 
epithelium. However, the excised nasal tissue model is also very hard to get, 
especially when large amount of fresh tissues are required. In addition, difficulty 
also lies in stripping the integral tissue from the lateral wall of the nasal cavity 
(Schmidt et al., 1998). 
Species differences between various animal nasal mucosae and between 
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animal and human nasal mucosae were reported by a few researchers (Zhou et al., 
1991; Wangensteen et al., 1993; Schmidt et a l , 1998; Dahl et al., 1998). Since the 
junction formed between goblet cells or between goblet cells and columnar cells 
are looser than that between columnar cells themselves, the proportion of goblet 
cells and columnar cells, which varies from one kind of animal to another, can 
influence the permeability of the nasal mucosa (Schmidt et al., 1998). Species 
differences are present in the activities of various nasal enzymes as well. Zhou et al. 
(1991) studied nasal enzyme activities in rats, rabbits, guinea pigs and dogs using 
nasal tissue homogenates and demonstrated the species differences in activities of 
aminopeptidases and esterases. As a matter of fact, such species differences exist in 
all in vitro, in situ and in vivo animal models. 
EpiAirway^ tissue 
Another tissue model that can be used for nasal drug delivery studies is the 
commercially available EpiAirway^M tissue from MatTek Corporation. It is 
cultured by the manufacturer from normal human tracheal/bronchial epithelial cells 
which will form a pseudo-stratified, highly differentiated tissue that closely 
resembles the epithelial tissue of the respiratory tract. EpiAirwayTM tissue is 
reported to be a suitable in vitro model for nasal drug delivery studies (Chemuturi 
et al., 2005; Leonard et al., 2005; Chen et al., 2006). Comparing with other in vitro 
models, the advantages of EpiAirway™ is obvious. First, the EpiAirway™ tissue 
model can be used immediately at arrival so that it may save a lot of time for cell 
culture. Second, the EpiAirway™ tissue is cultured from normal human respiratory 
epithelial cells and thus has a better differentiation than cancer cell lines. 
However, in order to maintain its viability, the total transit time of 
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EpiAirwayTM from USA, where the company is located at, to the targeted places 
should be less than 48 hours 一 including delays in customs. Therefore, it may not 
be practical for many researchers who are not in North America to use this tissue 
model. Moreover, this model is much more expensive than other in vitro models, 
which also limits its utilization. 
1.1.3.1.4 Cell lines 
Cultured models based on cancer cell lines with extended lifespan (or perhaps 
immortality) can overcome some of the limitations of the above mentioned in vitro 
models, such as the availability and reproducibility problems. At present, the 
commercially available cell lines that may be used for human nasal drug delivery 
studies are RPMI 2650 and Calu-3 cells (Dimova et a l , 2005). 
RPMI2650 cell line 
RPMI 2650 cell line is derived from human nasal septum squamous cell 
carcinoma. There are inconsistencies on the morphology and permeability of RPMI 
2650 cells. Several reports (De et al” 1995; Werner et al., 1996; Schmidt et al., 
1998) indicated that the differentiation of RPMI 2650 cells is low and the cells 
cannot form a confluent monolayer, which makes the model lack polarization. 
However, one study had successfully utilized this cell line to study the permeation 
of drugs from microspheres (Harikampakdee et al., 2006). 
Although it may not be suitable as a model for permeation studies, the RPMI 
2650 cell culture model is still useful for nasal metabolism studies (Dimova et al., 
2005). The aminopeptidase activity of RPMI 2650 cells is comparable with that of 
surgically excised human nasal, tissue. RPMI 2650 cells express leucine 
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aminopeptidase, aminopeptidase N, A, B and lysosomal aminopeptidase, and these 
enzymes may influence the nasal delivery of peptides and proteins. 
Calu-3 cell line 
Compared with RPMI 2650, the Calu-3 cells are much well studied. They are 
derived from human bronchial adenocarcinoma and have been reported to form 
"tight" polarized, mucus producing cell monolayers with apical microvilli (Foster 
et al., 2000; Mathias et al., 2002; Li et al., 2006; Grainger et al., 2006). However, 
the ability for calu-3 cells to form cilia needs to be further demonstrated (Grainger 
et a l , 2006). Some researchers reported the presence of cilia in Calu-3 cells 
(Pezron et al., 2002; Florea et al., 2003), whereas the others did not report cilia 
formation (Shen et a l , 1994; Foster et al., 2000; Mathias et al., 2002). At present, 
this cell line has been evaluated and utilized extensively for pulmonary drug 
transport studies. 
Although derived from human bronchia, Calu-3 cells have also been used as a 
surrogate for nasal epithelium. Seki et al. (2007) evaluated the enhancing effect of 
a sperminated gelatin on the nasal delivery of insulin in Calu-3 cell line model. Li 
et al. (2006) used the Calu-3 cell line model to study carbopol mediated transport 
enhancement of desmopressin across nasal epithelia. Witschi et al. (1999) utilized 
the Calu-3 cell line model to evaluate the effect of bioadhesive polymers on the 
nasal permeation of proteins. However, more information on the application of this 
cell line for nasal drug permeation studies is needed. 
1.1.3.2 In situ models 
Figure 1.3 shows the experimental set-up for the in situ nasal perfusion model. 
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The in situ model involves a series of complicated surgical procedures including 
anesthetizing the animal, cannulating the trachea from an incision made in the neck, 
and inserting a tube through the esophagus to the posterior part of the nasal cavity. 
The nasopalatine tract, which connects the nasal cavity to the mouth, is closed with 
an adhesive agent to prevent the drainage of drug solution from the nasal cavity to 
the mouth (Huang et al., 1985; Gizurarson, 1990). Rat is the most often used 
animal and rabbit is also used. The studied drug solution, which will be introduced 
into the nasal cavity through the abovementioned tube that is inserted through the 
esophagus to the posterior part of the nasal cavity, is placed in a reservoir and 
maintained at 37�C. A funnel is provided between the nose and the reservoir. The 
drug solution is then circulated through the nasal cavity of the animal by means of 
a peristaltic pump. The perfusion solution is introduced into the nasal cavity, and 
then passes out from the nostrils, into the funnel, and back to the reservoir. The 
drug solution in the reservoir is stirred constantly (Gizurarson, 1990; Hussain, 
1998). 
The extent of drug absorption can be determined by analyzing the amount of 
drug remaining in the perfusate at various time intervals (Huang et al., 1985). 
Blood sample collection is usually not necessary, since the in situ model is used for 
the study of the absorption rate or the absorption mechanisms of drugs and analysis 
of the perfusate samples can already meet such purpose. In addition, the perfusate 
samples are convenient to take and analyze as compared to plasma samples. 
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Figure 1.3 The experimental set-up for in situ nasal perfusion studies in the rat 
model. 1. Nasal cavity; 2. Nasal respiratory region; 3. Esophagus cannulation; 4. 
Trachea cannulation; 5. Nasopalatine; 6. Tongue; 7. Esophagus; and 8. Trachea. 
(Gizurarson, 1990) 
The in situ technique has been demonstrated to be useful to examine the effect 
of pH，osmotic pressure and enhancers (efficacy and safety) on nasal drug 
absorption (Aspden et al., 1996; Tengamnuay et al., 2000; Mitra et al., 2000; 
Olivier et al., 2001; Chavanpatil et al., 2002) and predict in vivo nasal drug 
absorption rate (Huang et al., 1985). The limitations of this model include: 1) due 
to the perfusion technology employed in the in situ model, the contact time 
between the drug and the nasal mucosa is prolonged as compared with that of the in 
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vivo nasal drug administration, which might give a false impression of improved 
absorption of the drug; 2) the mucus covering the epithelium can be gradually 
eroded by the perfusate thereby exposing the epithelium and increasing the drug 
absorption rate; and 3) the apparent absorption rate constant is dependent on factors 
such as the volume of the perfusate and the rate of perfusion, which makes 
comparisons of the absorption of drugs under different perfusion conditions 
difficult (Ugwoke et al., 2001). 
1.1.3.3 In vivo animal models 
In addition to in vitro and in situ models, nasal drug delivery studies have been 
performed in live animals including guinea pig, mouse, monkey, dog, sheep, rat, 
and rabbit (Gizurarson, 1990; Ilium, 1996; Ugwoke et a l , 2001). However, when 
comparing the results from different animal species and extrapolating them to the 
human situation, one should keep in mind the differences of nasal anatomy and 
metabolic capacity among various species. When selecting animal models for nasal 
drug delivery studies, the cost is usually the main factor that determines which 
animal model to use. 
1.1.3.3.1 Guinea pig 
Guinea pig is mostly used as an animal model for nasal immunization studies 
(Gizurarson, 1990). The respiratory region of guinea pig is covered by many goblet 
cells but few ciliated cells, which is quite different from human. The septum 
contains a so-called "septal window", so the two halves of the nasal cavity cannot 
be treated separately (Gizurarson, 1990). 
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1.1.3.3.2 Mouse 
Mouse is also mostly used for nasal immunization studies (Gizurarson, 1990). 
It may also be used in nasal toxicity studies (Ugwoke et al., 2001). 
Pharmacokinetic studies in mouse are limited due to its small size and small total 
blood volume. The nasal anatomy and the nasal respiratory epithelium of mouse 
are similar in most respects to those of other mammals (Gizurarson, 1990). The 
percentages of the nasal cavity of mouse covered by squamous, pseudostratified 
and olfactory epithelia are 7%, 46% and 47% respectively. Similar to guinea pig, 
the so-called "septal window" also presents in the septum of mouse (Gizurarson, 
1990). 
1.1.3.3.3 Monkey 
The monkey is not commonly used in nasal drug delivery studies, since it is 
very expensive and not easily accessible because its use is strongly opposed by 
animal rights groups (Ugwoke et al., 2001). Because both monkey and human are 
primates, it is often used in hormone studies (Gizurarson, 1990). Anatomically, 
monkey and human are very similar, so it is expected that nasal drug absorption in 
the monkey would be very similar to that in man (Ilium, 1996). However, to date, 
comparisons of the nasal drug absorption between monkey and human are not 
available. 
1.1.3.3.4 Dog 
Dog is often utilized as an animal model in nasal drug delivery studies, with 
beagle dog to be the most often used strain due to its docile nature (Ilium, 1996). 
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Dog can be used easily without being anesthetized or sedated. The nostrils of the 
dog are large so the nasal drug administration can be carried out easily. In addition, 
both pharmacokinetic and pharmacodynamic studies can be repeatedly performed 
on the same dog (Ugwoke et al., 2001). But the anatomy of the dog is quite 
different from that of man and it is more expensive than smaller animals such as rat 
and rabbit (Gizurarson, 1990). 
1.1.3.3.5 Sheep 
Sheep has only been used by a few researchers as an animal model for nasal 
drug delivery studies. Although cost for acquiring and keeping the sheep may be a 
concern, the more important reason for its limited use is that the surface of the 
respiratory system of the sheep is the major site for water vaporization to dissipate 
the body heat (Gizurarson, 1993). Especially under hot weather conditions, the rate 
of fluid production by the nasal glands of a sheep increases markedly, which may 
affect the nasal drug absorption (Gizurarson, 1990). Similar to the dog, 
pharmacokinetic and pharmacodynamic studies can be repeatedly performed on the 
same sheep (Ugwoke et al., 2001). 
1.1.3.3.6 Rabbit 
Rabbit is another popular animal model for nasal drug delivery studies. It is 
suitable for both pharmacokinetic and pharmacodynamic studies. Although it is 
relatively costly as compared to rats, the experiment can be repeated in the same 
rabbit after an appropriate drug washout and recovery period (Ugwoke et al., 2001). 
In addition, the relatively large total blood volume of a rabbit allows repeated blood 
• . 
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sampling. Moreover, the septum of rabbit is integrated, so there is a complete 
partition between the two halves of the nasal cavity (Ugwoke et al., 2001). 
1.1.3.3.7 Rat 
Rat is one of the most widely used animals for nasal drug delivery studies. 
Comparing with many other animals, rat is cheap and readily available.. However, 
the orifice of its nose is small, which makes the rat nasal drug administration not 
very easy (Ugwoke et al., 2001). A large surface area (50%) of the rat nasal cavity 
is covered by olfactory epithelium, whereas the percentage of olfactory epithelium 
is only 15% in man (Ilium, 1996). The rat usually undergoes a surgical operation 
following anaesthesia before the nasal drug administration. Since the septum of rat 
contains the so-called "septal window" which allows inter-cavity migration of 
drugs, rat cannot be used in a way that one "untreated" nostril being used as a 
control in toxicity studies (Gizurarson, 1990). 
1.1.4 Factors affecting drug absorption across nasal mucosa 
The factors affecting permeability of drugs through the nasal mucosa can be 
generally classified into three categories (Arora et al” 2002): 
1) Biological factors, including mainly mucociliary clearance, enzymatic 
activity, pH of the nasal cavity and transporters in the nasal mucosa. 
2) Physicochemical properties of drugs, including mainly molecular 
weight, solubility, distribution coefficient and pKa. 
3) Formulation factors, including mainly delivery systems, 
physiochemical properties of the formulation and device related 
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factors. 
1.1.4.1 Biological factors 
The information about biological factors can be useful in selecting drug 
candidates and designing nasal drug delivery systems. However, the biological 
factors are actually not easy to change. Moreover, if any of the biological 
conditions are about to be changed by the drug formulation, careful safety studies 
should be carried out to make sure that the physiological functions of the nose are 
not affected before its clinical application in human subjects. 
1.1.4.1.1 Mucociliary clearance 
The ciliated columnar cells are part of the nasal respiratory epithelium, 
bearing motile hair-like structures extending from its surface. The respiratory 
epithelium is covered by a mucus blanket, which is secreted by the submucosal 
glands and the goblet cells. This mucus blanket can be divided into two distinctive 
layers, a lower sol layer, which bathes the cilia, and an upper gel layer, which rests 
on the cilia (Ugwoke et al” 2001). The sol layer is less viscous with a thickness that 
is slightly less than the length of an extended cilium. The gel layer is more viscous, 
in which foreign particles and microorganisms get stuck. The cilia beat in close 
coordination in a metachronal wave by adjusting their frequency and phase of 
beating in response to cilia nearby (Marttin et al., 1998). Ciliary beat cycle has 
three phases. First, each cilium swings upwards and the tip penetrates into the gel 
layer. Then, the cilium bends towards the direction of the nasopharynx and this 
action continues, so at the end of this phase the whole cilium comes downwards 
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into the sol layer. In the last phase, the cilium recoils back to the initial position, 
ready for the next cycle (Satir et al., 1990; Ugwoke et al., 2001). This asymmetric 
beating enables movement of the overlying gel layer in one direction, while the 
underlying sol layer just moves forward and backward during this process. 
Therefore, the gel layer, together with the foreign substances that adhere to it, is 
propelled towards the nasopharynx, where it is swallowed into the gastrointestinal 
tract (Marttin et al., 1998). 
Through this mucociliary clearance system, the body removes foreign 
substances from the nasal cavity, thereby preventing them from reaching the lower 
airways (Marttin et al., 1998). Substances administered nasally are quickly cleared 
from the human nasal cavity, with a clearance half-life of 21 min (Soane et al., 
1999). However, this natural defense system largely limits the residence time of 
drugs administered nasally and thus limits the time for nasal drug absorption. To 
counter this limitation, application of mucoadhesive polymers which could prolong 
drug local residence time are broadly studied (Ugwoke et al., 2005). 
1.1.4.1.2 Enzymatic activity in the nasal cavity 
Researches have shown that the nasal mucosa including both the respiratory 
and the olfactory mucosa contains various drug metabolizing enzymes in 
substantial amounts. They are identified to be oxidative Phase I enzymes, 
conjugative Phase II enzymes, and proteolytic enzymes (Sarkar, 1992). The 
oxidative Phase I enzymes found in the nasal cavity include cytochrome P-450 
monooxygenases, flavin-containing monooxygenases, aldehyde dehydrogenases, 
epoxide hydroxylase, carboxylesterase and carbonic anhydrase (Sarkar, 1992). The 
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conjugative Phase II enzymes that exist in the nasal mucosa include glucuronyl 
transferase, sulfate transferase and glutathione transferase (Sarkar, 1992). 
Proteolytic enzymes present within the nasal cavity comprise exopeptidases, such 
as mono- and diaminopeptidases, and endopeptidases such as serine, cysteine, and 
aspartic proteinases (Costantino et a l , 2007). 
Although so many enzymes exist in the nasal mucosa, they do not appear to 
have a significant effect on the extent of absorption for most compounds except for 
peptides (Hussain, 1998). Hussain (1998) found that nasal bioavailabilities in 
animal and man of progesterone, testosterone, estradiol, naloxone, propranolol and 
butorphanol are almost 100% of that of the intravenous administration, whereas the 
oral bioavailabilities of these drugs range from 20-30% for propranolol to 0% for 
the others due to their extensive metabolism in gastrointestinal tract and liver. 
Sarkar (1992) also compared in vitro and in vivo nasal absorptions of progesterone 
in rat nasal mucosa. In the in vivo study, the nasal bioavailability after 
administration of progesterone to rats was 100% of that of the intravenous 
administration. However, extensive metabolism and uptake of progesterone was 
observed in the rat nasal mucosa in vitro. Both Hussain (1998) and Sarkar (1992) 
attributed their observations to the rapid absorption of the drugs by the nasal 
respiratory mucosa in vivo, which thereby makes the exposure time of the drug to 
the enzymes very short. 
In the case of peptides and proteins however, besides the resistance in 
penetrating the nasal mucosa resulted from their relatively large molecular weight 
(Sarkar, 1992), hydrolysis by peptidases does have an impact on their nasal 
bioavailability (Hussain, 1998). 
To overcome the barrier posed by the enzymes present in the nasal cavity, 
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researchers have developed methods such as use of prodrugs (Krishnamoorthy et 
al., 1998) and co-administration of drug with the enzyme inhibitors (Sarkar, 1992; 
Costantino et al., 2007). 
1.1.4.1.3 pH of the nasal cavity 
Washington et al. (2000) reported that the average baseline human nasal pH is 
about 6.3, with an overall range of 5.20-8.00. Such finding is higher than what was 
reported by Arora et al. (2002), where the pH of the nasal cavity in human was 
found to be between 5.5-6.5 in adults and 5.0-7.0 in infants. 
Greater drug permeation is usually achieved at a nasal pH at which more of 
the penetrant molecules exist as unionized species (Krishnamoorthy et a l , 1998). 
Therefore, a change in the pH can affect the ionization and thus increase or 
decrease the permeation of drug, depending on the nature of the drug (Arora et a l , 
2002). Because the pH of the nasal cavity can alter the pH of the formulation and 
vice versa, both the formulation pH and the membrane surface pH can affect the 
drug absorption (Behl et al., 1998a). To avoid nasal irritation, the ideal pH of a 
formulation should be within 4.5-6.5 and if possible the formulation should also 
have buffering capacity (Arora et al., 2002). While it is desirable to keep the 
formulation pH between 4.5 and 6.5, a pH out of this range may have to be chosen 
to keep an appreciable drug fraction in the unionized form. Therefore, benefit to 
risk ratio needs to be weighed in such cases (Behl et al., 1998a). 
1.1.4.1.4 Transporters in the nasal mucosa 
Drug absorption can be diminished by efflux transporters such as P-gp and 
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MRPl (Costantino et al., 2007). P-glycoprotein (P-gp) and multidrug 
resistance-associated protein 1 (MRPl) are members of the ATP-binding cassette 
transporters superfamily, which use the energy of ATP hydrolysis to regulate or 
energize the transport of a wide variety of substances (Wioland et a l , 2000). Two 
P-gp genes coding for MDRl and MDR3 proteins are present in humans 
(Costantino et al., 2007). 
P-gp (MDRl) and MRPl have been found in normal human nasal respiratory 
mucosa as evidenced by immunolocalization (Wioland et al., 2000). But the levels 
of P-gp (MDRl) in the human nasal respiratory epithelium are 125 times lower 
than that in the liver and 250 times lower than that in the jejunum and ileum 
(Bremer et al., 1992). P-gp is also found in both the bovine olfactory and nasal 
respiratory mucosae, and the expressed P-gp was capable of effluxing a substrate 
such as nasally administered etoposide. (Kandimalla et al., 2005a,b). The 
expression of P-gp seems to be greater in the olfactory epithelium compared to the 
nasal respiratory epithelium (Kandimalla et al., 2005b). MRPl is also present in 
bovine olfactory mucosa and is partly responsible for effluxing chlorpheniramine 
and chlorcyclizine from the olfactory mucosa (Kandimalla et a l , 2005a). 
Co-administration of inhibitors of efflux transporters through the nasal route, 
such as rifampin, quinidine and verapamil, may enhance the brain uptake of 
relevant substrates. However, this should be done with precaution since there are 
also efflux transporters on the blood-brain barrier (Graff et a l , 2003)，which 
protects effectively the brain from various xenobiotics. Inhibition of the efflux 
transporters on the blood-brain barrier may result in unwanted permeation of 
harmful xenobiotics into the cerebrospinal fluid. In addition, attention should also 
be paid to the side effects of the inhibitors. 
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1.1.4.2 Physicochemical properties of drugs 
Physiochemical properties of drugs are the key factors in selecting drug 
candidates and the excipients to be used in the drug formulation to achieve the 
intended therapeutic effect. 
1.1.4.2.1 Molecular weight 
Hussain (1998) and Arora et al. (2002) reported that nasal absorption of 
compound with molecular weight (MW) less than 300 Da was not significantly 
influenced by physicochemical properties other than MW of the drug. McMartin et 
al. (1987) compiled literature data on nasal absorption of nearly 30 different 
compounds with molecular weights varied from 160 to 34000 and concluded that: 
the nasal absorption of these drugs was via nonspecific diffusion through aqueous 
channels between cells of the nasal mucosa, which impose a size restriction on 
drug permeation. Therefore, drugs with molecular weight less than 300 Da in 
solution form can be absorbed rapidly via the aqueous channels in the nasal mucosa 
(Hussain, 1998). However, Gibson (1987) found that only a negligible nasal 
absorption of mannitol (MW 182) in rat was observed. Such discrepancies indicate 
that more studies are needed to illustrate the mechanism of nasal drug absorption. 
According to Donovan et al. (1998), compilations of data regarding the nasal 
absorption of large therapeutic agents, peptides and proteins in particular, along 
with more systematic studies using polymeric compounds have shown that nasal 
bioavailabilities of compounds larger than 1000 Da, can be directly predicted from 
their molecular weight. A number of studies showed that the percentage of 
absorption of a compound followed an inverse relationship with its molecular 
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weight (Behl et al.，1998a; Donovan et al., 1998; Costantino et al., 2007). In 
general, the nasal bioavailabilities of the large molecules with molecular weight 
greater than 1000 range from 0.5 to 5% (Donovan et al., 1998). 
To increase the nasal bioavailabilities of large molecules, a wide range of 
materials have been utilized as absorption enhancers. These enhancers usually 
work by affecting the morphology of the nasal mucosa, such as leaching of 
membrane proteins and opening of tight junctions (Donovan et al., 1990; Davis et 
al., 2003). Some of the enhancers are mucoadhesive polymers, and thus they 
enhance the drug nasal bioavailability by both affecting the morphology of the 
nasal mucosa and increasing the drug residence time. However, in the meantime, 
the enhancers might cause some irritations to the nasal mucosa. Therefore, 
extensive toxicological studies of the enhancers should be conducted to get enough 
safety information before their clinical application in human subjects. 
1.1.4.2.2 Solubility 
Typically, it is common that drugs are administered to the nasal cavity in the 
form of solution. However, only small volumes of drug solution can be applied to 
the nostrils due to the small volume of the nasal cavity. The optimal formulation 
volume for nasal administration is 25-200 |xl per nostril, with 100 |il being the most 
common. Larger volumes will drain out of the nose, reducing total absorption of 
the drug (Behl et al., 1998a). Therefore, the most concentrated form of a drug 
should be used (Wolfe et al., 2004). As a result, it is sometimes necessary to 
increase the solubility of the drug in order to allow its delivery in a therapeutically 
relevant dose. 
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There are several approaches to increase the solubility of poorly soluble 
compounds for their nasal administration, such as: 1) the use of prodrugs; 2) 
addition of cosolvents; 3) use of cyclodextrins as solubilizing excipients; and 4) 
choice of salt form (Costantino et al., 2007). It should be noted that 
dimethyl-P-cyclodextrin may also have an absorption enhancing effect on the nasal 
mucosa, in addition to its solubilizing and stabilizing effect (Behl et al., 1998b; 
Costantino et al., 2007). 
Sometimes, drugs may also be administered in the form of particulate nasal 
formulations, such as powder or suspension. In such occasions, a dissolution 
process will precede the absorption process (Behl et al., 1998a). No matter how，the 
particulate formulations are seldom used mainly due to the nasal mucociliary 
clearance defense system. When particulate nasal products are administered, the 
drug may be quickly cleared away from the nasal cavity before its complete 
dissolution and absorption. Therefore, the dissolution rate of the drug is very 
important. For drugs that are administered nasally to achieve a quick onset of 
action, particulate nasal products obviously cannot fulfill this task. 
1.1.4.2.3 Distribution coefficient and pKa 
The lipophilicity of a molecule is usually measured by its distribution 
coefficient D or partition coefficient P. D is the ratio of the sum of the 
concentrations of all species of the compound (ionized and neutral) in the two 
phases of a mixture of two immiscible solvents at equilibrium, while P is the ratio 
of the concentrations of the unionized compound in the two phases. Normally one 
of the solvents chosen is water, while the second is hydrophobic such as w-octanol. 
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D is pH-dependent, whereas P is independent on the pH of the solution. Therefore, 
D is more indicative of the lipophilicity of the collective species of the drug in 
certain solution. For un-ionizable compounds, P=D at any pH. 
The rate and extent of drug permeation through a biological membrane may 
be influenced by the lipophilicity of the compound. Huang et al. (1985) studied the 
nasal absorption of a series of barbiturates and Shao et al. (1994) studied the nasal 
absorption of a series of prodrugs of acyclovir, and both of them found that the 
extent of nasal absorption appeared to depend on the distribution coefficient (i.e. 
lipophilicity) of the drug. 
Shore et al. (1957) proposed the pH partition theory to explain the influence of 
GI pH and drug pKa on the extent of drug absorption. Unionized species of a drug 
are more lipophilic than ionized species, resulting in a better absorption of 
unionized species compared with ionized species. As described by the 
Henderson—Hasselbalch equation, the ratio of the concentration of ionized species 
[I] to unionized species [U] of a drug in the solution is a function of the pKa of the 
drug and the pH of the solution. Therefore, the drug absorption is greater at the pH 
where [U] is higher (i.e. distribution coefficient is higher). This theory is now being 
applied to drug absorption through various mucosae besides the gastrointestinal 
mucosa. Over two decades ago, Hirai et al. (1981) studied the nasal absorption of 
salicylic acid and aminopyrine at a series of pH and found that their absorption was 
highly dependent on the [U], supporting the pH partition theory. Later, there were a 
lot of other studies evaluating the effect of pH on the nasal absorption of various 
compounds, and most of them supported the pH partition theory, as reviewed by 
Behl et al. (1998a), Arora et al. (2002) and Costantino et al. (2007). 
However, it should be rioted that sometimes the nasal absorption of a drug 
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might be insensitive to the distribution coefficient (i.e. lipophilicity). According to 
Huang et al. (1985), large difference between the distribution coefficients of 
propranolol and L-tyrosine resulted in only a little difference in the nasal 
absorption rate constants for the two compounds. In the same article, they also 
reported that polar quaternary ammonium compounds were efficiently absorbed 
through the nasal mucosa. Behl et al. (1998a) concluded that the whole area of drug 
absorption through biological membranes in general was so complex that no single 
factor can explain the dynamics of drug absorption. 
1.1.4.3 Formulation factors 
Developing an appropriate formulation is very important for a drug. By 
selecting an optimal formulation and drug delivery device, a drug can become an 
effective and successful product. 
1.1.4.3.1 Delivery systems 
Specific types of drug delivery systems which are used to deliver formulations 
into the nasal cavity are important in determining the nasal absorption profiles of 
drugs. Choice of a certain dosage form generally depends on the drug being 
developed, indication being pursued, patient population, and marketing aspects 
(Behl et al., 1998a). Various nasal drug delivery systems that have been reported 
include conventional delivery systems such as nasal drops, solution sprays, 
suspension sprays, powders, gels, emulsions and ointments and novel delivery 
systems such as microspheres, liposomes, proliposomes and niosomes (Behl et al., 
1998a; Arora et a l , 2002). 
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Nasal drops are the simplest and most convenient form of nasal delivery 
system, but they cannot deliver an accurate amount of the formulation. The nasal 
drops were frequently used in the past when no metered-dose nasal devices were 
available (Behl et al., 1998a). Nowadays, solution sprays, suspension sprays and 
powders are usually delivered with a metered-dose device, such as actuator and 
nebulizer, which can precisely deliver medication volumes as low as 25 |xl (Behl et 
al., 1998a). Suspension sprays and powders are not as commonly used as solution 
sprays, probably owing to the aforementioned dissolution process before 
absorption and short clearance half-life. Suspension sprays and powders are also 
more expensive to manufacture because the metered-dose device has to be 
designed with the consideration of the size and morphology of the drug particles 
(Behl et al., 1998a). In addition, powders may cause irritation to the nasal mucosa 
(Arora et al., 2002). There was no method for delivering precise volume of gels 
until recently. Gels can reduce the post nasal drip and anterior leakage of the drug 
from the nasal cavity (Behl et al., 1998a). They also show mucoadhesive 
characteristics that slow down nasal mucociliary clearance, and thus the residence 
time of the drug in the nasal cavity is increased (Turker et al., 2004). Emulsions 
have also been investigated as vehicles for nasal drug delivery (Mitra et al., 2000; 
Li et al., 2002). But there are problems in delivering precise dose of emulsions 
from metered-dose devices, and the patient acceptance of nasal emulsion is low 
(Behl et al., 1998a). Very limited amount of work has been reported on ointments 
for nasal drug delivery. By the nature of ointments, they seem to be more 
appropriate for locally acting drugs than drugs for systemic delivery purpose (Behl 
et al., 1998a). 
Novel drug delivery systems, including microspheres, liposomes, 
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proliposomes and niosomes, have been developed for nasal drug delivery (Ahn et 
al., 1995; Jung et al., 2000; Arora et al., 2002; Ttirker et al., 2004). They can 
sustain the release of the entrapped drug and decrease the nasal mucociliary 
clearance due to their mucoadhesive characteristics. As a result, they may offer a 
sustained and higher permeation of the drug. That is why most of the work 
involving the use of these delivery systems is the delivery of macromolecules, such 
as insulin and growth hormone (Ttirker et al., 2004). 
Safety considerations should be taken into account for the delivery systems 
with mucoadhesive characteristics, since the nasal physiological conditions would 
be changed when such delivery systems are applied to the nasal cavity. 
1.1.4.3.2 Physiochemical properties of the formulation 
The physicochemical properties of the formulation that may influence drug 
permeation include: pH; osmolarity; and viscosity (for solutions and gels) of the 
formulation. 
The effect of pH on nasal drug absorption has already been discussed in this 
chapter earlier (section 1.1.4.1.3 and 1.1.4.2.3). 
According to Olivier et al. (2001)，hypoosmotic solution can significantly 
increase nasal absorption of midazolam in rat in situ model. But careful mucosal 
irritation assessments of hypoosmolarity are necessary, since Pujara et al. (1995) 
found that hypoosmotic solution could cause extensive cellular leakage of lactate 
dehydrogenase (LDH) on nasal epithelium using the rat in situ model. However, it 
should be noted that the results of these two reports are both based on the in situ 
model, in which the drug solutions were perfused into the nasal cavity and 
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circulated at certain rate with a pump for 1-2 hours. As a result of perfusion, the 
mucus covering the epithelium is gradually eroded by the perfusate thereby 
exposing the epithelium (Ugwoke et al., 2001) and the contact time of drug 
solution with the nasal mucosa is much longer than the actual in vivo drug 
residence time. In addition, the volume of the drug solution is much larger than the 
actual in vivo administration amount. Therefore，the in situ studies might 
overestimate both the nasal absorption enhancement and the nasal mucosal 
irritation by hypoosmotic solutions. 
Harris et al. (1989) studied the effect of viscosity on the nasal absorption of 
desmopressin and found that although the addition of a viscous agent 
(methylcellulose) to nasal solutions may produce a more sustained effect, it delays 
the absorption and no enhancement is achieved in the total bioavailability. 
However, this conclusion might not be applicable to all viscous agents or drugs. In 
a study by Morimoto et al. (1985), the polyacrylic acid gel base significantly 
enhanced the absorption of insulin and calcitonin via the nasal cavity, whereas the 
absorption of insulin from 1% (w/v) carboxymethyl cellulose solution was 
negligible. The authors also found that the nasal absorption of insulin in 0.1% (w/v) 
polyacrylic acid gel base was greater than that from 1% (w/v) polyacrylic acid gel 
base. This indicates that there seems to be an optimum concentration and viscosity 
for the polyacrylic acid gel base, which warrants further studies. 
1.1.4.3.3 Device related factors 
Factors related to the nasal administration devices that may influence nasal 
drug absorption include: droplet or particle size, spray pattern, plume geometry, 
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and site of deposition (Ugwoke et al., 2001; Newman et al., 2004). 
The droplet or particle size determines the likelihood of deposition within the 
nasal cavity by inertial impaction that occurs following a change in the direction of 
air flow. Spray pattern and plume geometry define the shape of the expanding 
aerosol cloud, and thus determine the site and pattern of deposition (Newman et al., 
2004). The drug permeability across the site at which the formulation is deposited 
and the area of nasal cavity exposed to the drug formulation affects the overall 
nasal absorption of drugs (Arora et al” 2002). 
Various devices such as dropper, squeezed bottle and spray pump were used 
to deliver drugs to the nasal cavity in the past, but more sophisticated devices that 
can exert a better performance are preferred nowadays. A number of researchers 
have been working on improving nasal drug delivery devices, and some of them 
have developed effective and accurate nasal dosing devices (Keldmann, 2005; 
Giroux，2005; OptiNose, 2005). Among these studies, what is the most worth 
mentioning is the Controlled Particle Dispersion™. Rather than a single device, 
Controlled Particle D i s p e r s i o n " ™ is a versatile nasal drug delivery technology 
platform that delivers optimal nasal deposition with formulation flexibility to work 
successfully with the many variables of the formulation (Giroux, 2005). 
1.1.5 Profile of a suitable drug candidate for nasal delivery 
The nasal route of drug administration may not be applicable to all drugs for 
the following reasons (Behl et a l , 1998a; Ugwoke et a l , 2005): 1) Despite the high 
permeability of the nasal epithelium, some drugs, such as drugs with large 
molecular weight and high hydrophilicity, may not be sufficiently absorbed; 2) 
Since only small volumes of drug solution can be applied to the nostrils, the drug 
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solution administered is usually highly concentrated. Therefore, lack of adequate 
aqueous solubility is often a barrier for the nasal drug administration; 3) Some 
drugs can cause nasal irritation; 4) Nasal drug delivery may not be suitable for 
therapies requiring chronic dosing, unless the long-term investigation has excluded 
potential nasal toxicity or irritation of the drug formulation; 5) Drugs requiring 
sustained blood levels can hardly be considered for nasal delivery, due to the 
limited drug residence time in the nasal cavity resulted from nasal mucociliary 
clearance system. 
Based on the advantages and limitations of nasal drug delivery, Behl et al. 
(1998a) concluded that an ideal nasal drug candidate should possess the following 
attributes: 
—appropriate aqueous solubility to provide the desired dose in a 25-150 |xl 
volume of formulation administered per nostril; 
—appropriate nasal absorption properties; 
— n o nasal irritation from the drug; 
— a suitable clinical rationale for nasal drug delivery, e.g. rapid onset of 
action; 
— l o w dose. Generally, below 25 mg per dose; 
— n o toxic nasal metabolites; 
— n o offensive odors/aroma associated with the drug; 
—suitable stability characteristics. 
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1.2 Physicochemical properties and human pharmacokinetics of 
the four drug candidates 
Based on the above criteria, four drug candidates with potential therapeutic 
advantages for nasal delivery were selected for the current study. Among the four 
candidates, rizatriptan is for treatment of migraine, meloxicam and lomoxicam are 
for rapid analgesic therapeutic usage, and nebivolol is useful in treatment of angina 
cordis. Their physicochemical properties are summarized in Table 1.1. Most of the 
data are calculated values obtained from ACD/Labs Software (Advanced 
Chemistry Development Inc., Canada). In addition, experimental data are also 
provided if available. Moreover, the available information of the human 
pharmacokinetics of the above drug candidates is reviewed below. 
1.2.1 Rizatriptan 
Rizatriptan is an active serotonin 5-HTl receptor agonist that potently and 
selectively binds to 5-HTlB/lD subtypes (Wellington et a l , 2002). It is used to 
treat acute migraine attacks, but it does not prevent future migraine attacks. At 
present, rizatriptan is administered through the oral route with regular release 
tablets and oral disintegrating tablets being commercially available. The 
recommended initial dose for rizatriptan is 5 or 10 mg. If required, additional doses 
for headache recurrence should be separated by at least 2 hours. No more than 30 
mg should be taken during a 24 hour period. 
Oral rizatriptan is readily absorbed from the gastrointestinal tract (-90%), but 
it experienced a moderate first-pass effect, resulting a bioavailability of about 47% 
(Vyas et al., 2000). The bioavailability and Cmax of rizatriptan are similar following 
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administration of regular tablets and oral disintegrating tablets, but the rate of 
absorption is somewhat slower with oral disintegrating tablets. After administration 
of regular tablets, mean peak plasma concentrations (Cmax) are reached in 
approximately 1-1.5 hours ( T m a x ) , while Tmax of oral disintegrating tablets averages 
1.6-2.5 hours (FDA, label information). The presence of a migraine headache did 
not appear to affect the absorption or pharmacokinetics of rizatriptan. Food has no 
significant effect on the bioavailability of rizatriptan but delays the time to reach 
peak concentration by an hour (FDA, label information). Goldberg et al. (2000) 
reported that the average Cmax after oral administration of 10 mg rizatriptan was 
19.6 ng/ml. 
The mean volume of distribution for rizatriptan is approximately 140 liters in 
male subjects and 110 liters in female subjects. Rizatriptan is minimally bound 
(14%) to plasma proteins (Wellington et al., 2002; FDA, label information). 
Rizatriptan undergoes extensive hepatic metabolism by monoamine oxidase A 
(MAO-A), primarily to inactive metabolites (mainly triazolomethyl-indole-3-acetic 
acid). The only active metabolite of rizatriptan is N-monodesmethylrizatriptan, the 
activity of which is similar to that of parent compound at the 5-HTlB/lD receptor. 
Plasma concentrations of N-monodesmethylrizatriptan are approximately 14% of 
those of parent compound, and it is eliminated at a similar rate as the parent 
compound (Goldberg et al., 2000; Wellington et al., 2002). 
After a single oral dose of 10 mg ^"^C-rizatriptan, 82.4% of the radioactivity 
was excreted in the urine, while the radioactivity excreted in the faeces was 15.2%. 
Approximately 14% of the administered dose was excreted in urine as unchanged 
rizatriptan, while 51% is excreted as indole acetic metabolites (Wellington et a l , 
2002). The elimination half-life (ti/2) is 2.12 hours after a single oral dose of 10 mg 
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rizatriptan (Goldberg et al., 2000). 
1.2.2 Meloxicam 
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) which 
decreases prostaglandin synthesis by inhibiting cyclo-oxygenase (COX). It exhibits 
analgesic, antipyretic and anti-inflammatory effects. The usual recommended oral 
dose is 7.5 — 15 mg/day; sometimes 30 mg/day may also be employed. It 
significantly decreases symptoms of pain with a low incidence of gastrointestinal 
side effects. Meloxicam has been shown, especially at its low therapeutic dose, to 
selectively inhibit COX-2 over COX-1 (Tiirck et al., 1996). At present, a parenteral 
formulation of meloxicam (15 mg/1.5 ml) has been developed for situations 
requiring rapid analgesia, such as acute mechanical lower back pain, sciatica and 
acute flares of osteoarthritis (Davies et a l , 1999). 
The absolute bioavailability for oral meloxicam capsules after a single 30 mg 
dose was 89%. The absorption of meloxicam is independent of dose over the range 
7.5-30 mg (Tiirck et al., 1996). The effect of food on absorption of meloxicam need 
to be further demonstrated. Busch et al. (1991) reported that there were no 
detectable differences in bioavailability when meloxicam was given following food. 
But Turck et al. (1996) reported that the Cmax occurred later (Tmax was doubled) 
when meloxicam was administered in a fasted state. Maximum meloxicam plasma 
concentrations (Cmax) were reported to be achieved 6-11 h (T^ax) after oral 
administration (Turck et al” 1996; Davies et al., 1999), while absorption after 
intramuscular injection is faster, with Cmax occurring after 1-1.5 h (Narjes et al., 
1996). After a single oral dose of 15 mg, meloxicam reaches a Cmax of about 0.93 
mg/L (Tiirck et al., 1996). Turck et al. (1996) reported that the plasma 
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concentration-time profile showed multiple peaks after Cmax, which indicates a 
recirculation of the drug in the gastrointestinal tract. 
Meloxicam is strongly bound to serum albumin (>99%). Such high protein 
binding results in a restricted volume of distribution of 10-15 L (0.1 to 0.2 L/kg), 
which approximates the extracellular fluid volume (Davies et al., 1999). Although 
meloxicam is predominantly distributed to highly perfused (albumin rich) 
compartments such as the blood, liver, kidney, etc., it could readily penetrate into 
other tissues (Turck et al., 1996). For example, synovial fluid concentrations of 
meloxicam are approximately half of the corresponding plasma concentrations. 
Also, high concentrations of meloxicam in inflamed tissue have been observed in 
animal models. Since adverse central effects, such as headaches and dizziness, have 
been reported in a small number of recipients of NSAIDs, neural penetration of 
meloxicam was studied in rats (Jolliet et al” 1997). Following rapid carotid 
injection into rats, a rather low percentage (19%) of administered radiolabelled 
meloxicam was recovered from brain homogenates following decapitation 5 
seconds after injection. 
Meloxicam is almost exclusively eliminated by metabolic degradation in liver 
to four pharmacologically inactive metabolites. Only trace amount of the 
unchanged parent compound are excreted in the urine (0.2%) and faeces (1.6%). 
The main metabolites of meloxicam are independent of route of administration 
(Davies et al., 1999). The cytochrome P450 2C subgroup of isoenzymes, most 
probably 2C9, plays a major role in oxidative metabolism of meloxicam. The 
apparent oral clearance of meloxicam ranges from 0.42 to 0.7 L/h (Davies et a l , 
1999). The elimination half-life (ti/2) is about 20 h (Turck et a l , 1996). 
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1.2.3 Lornoxicam 
Lomoxicam is a nonsteroidal anti-inflammatory drug (NSAID) with potent 
analgesic and anti-inflammatory activity. Like other NSAIDs, the analgesic and 
anti-inflammatory activity of lomoxicam is related to its inhibitory action on 
prostaglandin synthesis, via inhibition of cyclo-oxygenase activity (Skjodt et al., 
1998). In addition, activation of the opioid neuropeptides system may be a 
component of the analgesic effect of lomoxicam. Because of its potent analgesic 
effect, lomoxicam is used as injection to treat acute moderate post-operative pain 
after surgery and pain associated with acute lumbo-sciatica, besides the common 
use of oral NSAIDs in the treatment of inflammatory arthropathies, mechanical soft 
tissue pain and migraine. The commercially available oral tablets of lomoxicam are 
4 mg or 8 mg per tablet, the powder for injection contains 8 mg lomoxicam per vial. 
Total daily dose of lomoxicam should not exceed 16 mg. 
Hitzenberger et al. (1990) reported that when 4 mg lomoxicam was orally 
administered as an aqueous solution to fasted subjects, the drug was absorbed 
rapidly and completely with a Tmax of 0.5 hour, a Cmax of 325 ng/ml and a 
bioavailability of 105%. However, when administered as tablets, lornoxicam 
reached peak plasma concentrations (Cmax) within an average of 2 to 3 hours 
(Olkkola et al., 1994). Intragastric food reduces and delays the absorption of 
lomoxicam as demonstrated by an approximate 15% decrease in AUC and an 
increase in Tmax (Skjodt et al., 1998). The bioavailability of lomoxicam following 
intramuscular administration is estimated to be 87%. 
The volume of distribution of lomoxicam is between 5 and 10 L in humans 
(0.1 to 0.2 L/kg), which approximates extracellular fluid volume and is consistent 
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with that of other -oxicams. Within this volume of distribution, lomoxicam is 
strongly protein bound (about 99.7%), almost exclusively to serum albumin 
(Hitzenberger et al., 1990). Lomoxicam can penetrate into perivascular spaces 
readily, including the synovial fluid (Skjodt et al., 1998). 
Lomoxicam is almost exclusively cleared by hepatic metabolism. Three 
metabolites of lomoxicam were identified, with 5 ‘ -hydroxy-lomoxicam as the main 
one and the other two structurally unidentified polar metabolites as the minor ones. 
The renal clearance of the unchanged drug is negligible (Hitzenberger et al., 1990). 
The metabolism of Lomoxicam is largely mediated through cytochrome P450 2C 
subgroup of isoenzymes, most probably 2C9. Zhang et al. (2005) reported that the 
pharmacokinetics of lomoxicam is highly dependent on CYP2C9 polymorphism. 
The presence of the CYP2C9*3 allele particularly impairs its metabolism and 
should be clinically relevant to poor metabolizers. 
The mean elimination half-life (ti/2) of lomoxicam is 3 to 5 hours, with 
considerable inter-individual variability. The apparent oral clearance of lomoxicam 
4 to 8 mg twice daily ranges from 1.5 to 3.4 L/h (Skjodt et al., 1998). 
1.2.4 Nebivolol 
Nebivolol is a novel beta 1-blocker combines beta-adrenergic blocking activity 
with a vasodilating effect. It is devoid of intrinsic sympathomimetic or membrane 
stabilizing activity but appears to mediate the release of endothelium-derived nitric 
oxide and thus can result in vasodilation (McNeely et al., 1999). In addition to be 
utilized to treat hypertension like other -olols, nebivolol is useful in treatment of 
angina cordis and atherosclerosis, and can improve the function of the left cardiac 
ventricle of patients suffering from congestive heart failure. At present, the drug is 
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given through the oral route as tablets, which contain 5mg nebivolol each. The 
daily dose of nebivolol for adults is 5 mg. Nebivolol is clinically administered as a 
racemic mixture of equal proportions of the enantiomeric pair, SRRR (d) and RSSS 
(1). The separate enantiomers have unequal potency with respect to beta-receptor 
activity and nitric oxide-mediated vasodilation, but the combination appears to 
have greater antihypertensive activity than either enantiomer alone (McNeely et al., 
1999). 
Nebivolol is rapidly absorbed after oral administration with a Tmax of about 0.5 
to 2.0 hours. Its absorption is not significantly affected by the presence of food. The 
metabolism of nebivolol is subject to genetic polymorphism, so individuals may be 
phenotypically characterized as poor or extensive metabolizers. The bioavailability 
of nebivolol is 96% in poor metabolizers and 12% in extensive metabolizers 
(McNeely et al., 1999). 
Plasma protein binding for each enantiomer (d- and 1-nebivolol) is about 98% 
(McNeely et al., 1999). Nebivolol is a highly lipophilic drug. Since obesity may 
modify the distribution and thus elimination of lipophilic drugs, Cheymol et al. 
(1997a) compared the distribution volume of nebivolol in obese and normal 
subjects. They found that the distribution of nebivolol in the adipose tissue in obese 
subjects is limited, despite its high lipophilicity. So they concluded that the 
distributions of the drug nebivolol in obese and lean individuals are similar. 
After oral administration, nebivolol undergoes extensive first-pass metabolism 
(McNeely et al” 1999). It is metabolized in the liver through CYP2D6-dependent 
aromatic hydroxylation, which produces active beta-blocking hydroxylated 
metabolites. Polymorphic variants of CYP2D6 responsible for the poor metabolizer 
phenotype markedly alter the pharmacokinetics of the drug, compared with its 
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pharmacokinetics in extensive metabolizers. But the influence of polymorphisms 
on nebivolol，s antihypertensive efficacy was not significant, because the formation 
of the active hydroxylated metabolites could compensate for the low concentration 
of unchanged drug in extensive metabolizers (Lefebvre et al., 2007). 
The elimination half-lives (ti/2) of both nebivolol enantiomers (d- and 
1-nebivolol) are about 10 hours in extensive metabolizers, while those in poor 
metabolizers could increase by up to 5 times. Elimination half-lives for the 
hydroxylated metabolites for both enantiomers average about 24 hours in extensive 





































































































































































































































































































































1.3 Scope of the current study 
Although a number of models have been developed for nasal drug delivery 
studies, there is no well validated and readily accessible in vitro biological model 
that is suitable for rapid screening for nasal drug delivery at present. Among the 
existing in vitro biological models, Calu-3 cell line model seems to be the most 
promising one that might be qualified for this purpose. The reasons are as follows: 
1) Although Calu-3 cells were derived from human bronchia, researchers have 
reported that there was little difference between the primary cultured nasal and 
bronchial epithelial cells with respect to either their morphology or ciliary activity 
(Devalia et al. 1990; Devalia et al., 1991); 2) Other cultured bronchial epithelial 
cells (EpiAirwayTM) have been found to be suitable for nasal drug delivery studies; 
3) Although information on its application for nasal drug permeation screening is 
insufficient, Calu-3 cell line model has already been used in nasal drug delivery 
studies (Witschi et al., 1999; Li et al., 2006; Seki et al., 2007). 
The present study aims to develop Calu-3 cell line model as an in vitro model 
for nasal drug permeation screening. 
In order to reach the overall goal, several specific studies will be carried out. 
First, the Calu-3 cell line model will be developed and preliminarily validated. 
Second, to investigate the ability of Calu-3 cell line for nasal drug screening, the 
permeations of four selected drug candidates with potential therapeutic advantage 
of nasal delivery will be evaluated using this model. Finally, in vivo nasal 




Preliminary validation of Calu-3 cell line model as an in 
vitro model for nasal drug permeation screening 
2.1 Introduction 
The Calu-3 cells are derived from human bronchial adenocarcinoma and have 
been reported to form "tight" polarized, mucus producing cell monolayers with 
apical microvilli (Foster et al., 2000; Mathias et al., 2002; Li et al.，2006; Grainger 
et al., 2006). At present, this cell line has been evaluated and utilized extensively 
for pulmonary drug transport studies. Although derived from human bronchia, 
Calu-3 cells have also been used as a surrogate for nasal epithelium. Seki et al. 
(2007) evaluated the enhancing effect of a sperminated gelatin on the nasal delivery 
of insulin in Calu-3 cell line model. Li et al. (2006) used the Calu-3 cell line model 
to study carbopol mediated transport enhancement of desmopressin across nasal 
epithelia. Witschi et al. (1999) utilized the Calu-3 cell line model to evaluate the 
effect of bioadhesive polymers on the nasal permeation of proteins. However, at 
present there is inadequate information on the application of Calu-3 cell line for 
nasal drug permeation screening studies of small molecules. 
The objective of the current study is to preliminarily validate the Calu-3 cell 
line model so as to demonstrate that this model developed in our lab exhibits 
similar characteristics as demonstrated by other published studies and is suitable 





[^H] -Dexamethasone (250|iCi) was purchased from GE Healthcare 
Bio-Sciences Corp. (USA). [“Cj-Mannitol (50|aCi) and phosphate buffered saline 
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tablet were supplied by Sigma-Aldrich Co. (USA). [ H]-Testosterone (250 jiCi) and 
[^H]-water were ordered from Amersham Biosciences (UK). [^"^CJ-PEG 4000 (0.5 
mCi/g) was obtained from PerkinElmer Life Sciences (USA). Propranolol 
hydrochloride was purchased from Chang Zhou Guangming Biochemical 
Laboratories (BP 2000/USP24). OptiPhase HiSafe 3 scintillation cocktail was 
supplied by PerkinElmer Life Sciences (Finland). CellTiter 96® AQueous One 
Solution Cell Proliferation Assay was provided by Promega Corporation (USA). 
HPLC grade acetonitrile was obtained from Lab Scan Asia Co. (Thailand). 
Triethylamine was purchased from BDH Laboratory Supplies (England). Other 
chemical reagents used were at least of analytical grade. 
2.2.2 Materials for cell culture 
Calu-3 cell line (Passage 18) was obtained from the American Type Culture 
Collection (USA). Dulbecco's Modified Eagle Medium Nutrient Mixture F-12 
(Ham, 1:1, with L-Glutamine, 2.438 g/L Sodium Bicarbonate), Fetal Bovine Serum 
(certified), Non-Essential Amino Acids (xlOO), Penicillin-Streptomycin (10000 
units/ml penicillin G sodium and 10000 |ag/ml streptomycin sulfate), 
Trypsin-EDTA (0.25%) and Hank's Balanced Salt Solution (HBSS) were supplied 
by Invitrogen (USA). Collagen type I (from rat tail) was provided by 
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Sigma-Aldrich Co. (USA). Pipettes (5 ml and 10 ml) and 12 well Transwell® plates 
(0.4 [ivn pore size, 1.12 cm^, polycarbonate membrane insert) were purchased from 
Coming Costar Co. (USA). Tissue culture flasks (75 cm】)，centrifuge tubes (15 ml 
and 50 ml), 96-well plates and other cell culture consumables were supplied by 
IWAKI (Japan). 
2.2.3 Instruments 
The HPLC system consists of a Waters 2695 solvent delivery module, a 
Waters 996 photodiode array (PDA) detector and a BDS Cis reversed phase column 
(4.6 mm I.D. x 250 mm, 5 [im, Thermo Hyersil). Other instruments used include: a 
Benchmark Microplate Reader from Bio-Rad Laboratories Inc. (USA), a Leica 
Precision Inverted Microscope from Leica Co. (Germany), an epithelial 
voltohmmeter from World Precision Instruments (USA), and a TRI-CARB 2900TR 
Liquid Scintillation Analyzer from PerkinElmer (USA). 
2.3 Methods 
2.3.1 Cell culture 
Calu-3 cells from the American Type Culture Collection (ATCC) were 
cultured in 75 cm^ flasks using 15 ml medium and incubated at 37°C in 90% 
relative humidity atmosphere of 5% C02-95% air. The medium was prepared with 
500 ml Dulbecco's Modified Eagle Medium Nutrient Mixture F-12 (1:1), 50 ml 
fetal bovine serum, 5 ml nonessential amino acid solution and 5 ml 
penicillin/streptomycin solution (10000 units/ml penicillin G sodium and 10000 
|ig/ml streptomycin sulfate). The medium was changed every other day. When 
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reached 70%-80% confluence, the cells were dissociated with 5 ml 0.25% 
Trypsin-EDTA solution, then subcultured at a split ratio of 1:3 or seeded in the 
Transwell® inserts. Before seeding the cells, the Transwell® inserts were coated 
with a collagen layer. Cells were seeded on the apical surface of Transwell® inserts 
at a density of 2x1 O^  cells/well in 0.2 ml medium, followed by adding 0.8 ml 
medium to the basolateral chamber. Two days after seeding, the medium in the 
apical chamber was withdrawn to create an air-interfaced culture condition. The 
medium in the basolateral chamber was replaced every two days. For storage of 
Calu-3 cells, the cells were suspended in the cryoprotectant medium, which 
consisted of 95% culture medium and 5% DMSO, and stored in liquid nitrogen. 
2.3.2 Cytotoxicity studies by MTS/PES assay 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS/PES 
assay) is a colorimetric method for determining the number of viable cells in 
proliferation or cytotoxicity assays. The CellTiter 96® AQueous One Solution 
Reagent contains a novel tetrazolium compound MTS 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt] and an electron coupling reagent PES (phenazine 
ethosulfate). The MTS tetrazolium compound can be metabolized by living cells 
into a colored formazan product that is soluble in tissue culture medium. This 
conversion is presumably accomplished by NADPH or NADH produced by 
dehydrogenase enzymes in metabolically active cells (Berridge et al., 1993). 
Usually excess amount of MTS is added in the reaction system so as to saturate the 
dehydrogenase enzymes. Under such condition, the quantity of formazan product 
as measured by the absorbance at 490 nm by Microplate Reader is directly 
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proportional to the number of living cells in culture. 
2.3.2.1 Optimization of MTS/PES assay for the initial cell seeding 
density and the incubation time 
Calu-3 cells grew in flasks were detached with 0.25% Trypsin-EDTA when 
reached 70-80% confluence. The cell concentration was estimated by 
haemocytometer after staining with Trypan blue. Then the cells were diluted with 
the culture medium to reach a series of cell seeding densities. A 100 jil of the 
diluted cells in culture medium was added in 96-well plates to obtain the initial cell 
seeding densities of 100, 500, 1000，2500, 5000, 7500，10^ 5x10^ and 10^ 
cells/well, respectively. The 96-well plates were then incubated for 24 h or 48 h 
respectively. After the incubation, the culture medium in the wells was aspirated 
carefully, followed by addition of 100 i^l HBSS as well as 20 MTS/PES solution 
into each well. The 96-well plates were incubated for another 4 hours. The optical 
density (OD) of the final incubated solutions in each well was recorded at 490 nm 
by Microplate Reader with the wells containing 20 |il MTS/PES solution and 100 
HBSS (without cells) as blank. 
2.3.2.2 Cytotoxicity studies of non-physiological pH and osmolality 
on Calu-3 cells by MTS/PES assay 
Based on results obtained in section 2.3.2.1, Calu-3 cells were seeded in 
96-well plates with an initial cell seeding density of 5000 cells/well in 100 \i\ 
culture medium. The plates were incubated for 48 h at 3 7 � C in 90% relative 
humidity atmosphere of 5% C02-95% air. After removal of the medium, 100 |xl test 
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solution, i.e. phosphate buffered saline (PBS) with different pH or osmolarity, was 
added to each well. PBS with physiological pH and osmolarity (pH 7.4，280 mOsm) 
was employed as a negative control. The 96-well plates were incubated for another 
2 hours followed by replacing the test solution with 100 HBSS and 20 |il 
MTS/PES in each well. After incubation of the 96-well plates for another 4 hours, 
the optical density of each well at 490 nm was measured by Microplate Reader. 
The wells with 20 i^l MTS/PES solution and 100 HBSS (without cells) were 
used as blank. 
2.3.3 Integrity of Calu-3 cell monolayers 
The integrity of Calu-3 cell monolayers was monitored by monitoring both the 
transepithelial electrical resistance (TEER) and permeabilities of various marker 
compounds. In addition, the effect of osmolarity on the integrity of Calu-3 cell 
monolayers was also studied. 
2.3.3.1 Transepithelial electrical resistance (TEER) 
The electrical resistance of the Calu-3 cell monolayer was measured using the 
epithelial voltohmmeter. The TEER was calculated by subtracting the resistance of 
the cell free Transwell® culture insert and correcting for the surface area of the 
insert. To decide the appropriate TEER values that can indicate the integrity of the 
Calu-3 cell line model for the permeation studies, the TEER values were measured 




2.3.3.2 Permeabilities of marker compounds 
[14c]-Mannitol and [^'^Q-PEG 4000 were commonly used as paracellular 
markers (Pezron et a l , 2002; Wadell et a l , 2003). [^H]-Dexamethasone, 
[^H]-Testosterone and propranolol were usually used as transcellular markers 
(Nielsen et al., 2000; Mathias et al., 2002; Wang, 2005). Tritiated water was also 
used as a marker, and was expected to transport across the cell monolayer freely 
(Nielsen et a l , 2000). 
2.3.3.2.1 Cytotoxicity of marker compounds by MTS/PES assay 
Calu-3 cells were seeded in 96-well plates with an initial cell seeding density 
of 5000 cells/well in 100|il culture medium. The plates were incubated for 48 hours 
at 37�C in 90% relative humidity atmosphere of 5% C02-95% air. After removal of 
the medium, lOOjil test solutions containing marker compounds dissolved in HBSS 
(pH 7.4，280 mOsm) at different concentrations, were added to each well with 
blank HBSS (pH 7.4，280 mOsm) as the negative control. The plates were 
incubated for another 2 hours followed by replacing the test solutions with 100 jil 
HBSS and 20^1 MTS/PES solution in each well. The plates were then incubated for 
another 4 hours before measuring the optical density of each well at 490 nm with 
Microplate Reader. The wells with 20 |xl MTS/PES solution and 100 |il HBSS 
(without cells) were used as blank. 
2.3.3.2.2 Permeabilities of markers 
The permeabilities of markers were examined by measuring their apparent 
permeability coefficients ( P a p p ) . [^"^C]-Mannitol, [^"^CJ-PEG 4000， 
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[^H]-Dexamethasone, [^H]-Testosterone and [^H]-water were diluted or dissolved 
in HBSS (pH 7.4, 280m0sm) with a final concentration of 10^ \ 0 \ lO;，500 and 
200 nCi/ml, respectively. Propranolol was dissolved in HBSS to reach a 
concentration of 10"^  M. 
On the day of experiment, the medium in the basolateral chamber of the 
Transwell® plate was removed. After washing with 37°C HBSS, the cell 
monolayers were equilibrated in HBSS (0.2 ml in apical chamber, 0.8 ml in 
basolateral chamber) at 37�C for 10 min. Then, the HBSS in the apical chamber 
was aspirated and 0.2 ml of pre-warmed test solutions (37�C) were added to the 
apical chamber. Samples (100 were taken from the basolateral chamber at 
various time intervals, and the same amount of 3TC HBSS was supplemented 
immediately after every sampling to maintain the constant volume of the fluid in 
receiver chamber. At the end of the experiment, 100 |il samples were taken from 
both the apical and basolateral chambers to calculate the recovery of the tested 
compounds according to the following equation: 
Recovery (%) = (Aapical + Abasolateral)丨 A q ><100% (2.1) 
Where Aq is the initial amount of the marker, AAPICAI and ABASOIATERAI are the 
amount of the marker in the apical and basolateral chambers at the end of the 
permeation studies. 
For the radiolabelled samples, they were mixed with 1.5 ml scintillation 
cocktail and their radioactivity was determined in the liquid scintillation counter. 
The concentrations of propranolol in the samples were determined using an HPLC 
method which was previously developed and validated in our group (Wang, 2005). 
The mobile phase, containing 35% acetonitrile and 65% 25 mM phosphate buffer 
(pH 4.0) with 0.5% triethylamine, was run with the isocratic mode. The flow rate 
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was set at 1.0 ml/min and the UV measurement was conducted at 213nm. The 
apparent permeability coefficient was calculated according to equation 2.2. 
Papp=(dQ/dt)/(A-Co) (2.2) 
Where dQ/dt (mol/sec) is the steady-state rate of change in cumulative mass 
permeated, A (cm�）is the surface area for permeation, and Co (mol/ml) is the initial 
dosing concentration in the donor chamber. 
2.3.3.3 Effect of osmolarity on the Calu-3 cell monolayers 
Effect of osmolarity on the barrier function of Calu-3 cell monolayers was 
examined first by monitoring the changes in TEER before and after a 2 hour 
incubation with hypoosmotic (70 mOsm), isosmotic (280 mOsm) and 
hyperosmotic (560 mOsm) phosphate buffered saline plus (PBS+) (pH 7.4)， 
respectively. The PBS+ was prepared by supplementing 200 ml of PBS with 90 |il 
of 2M CaCb and 80 \i\ of IM MgCb. In addition, the permeations of paracellular 
marker [^"^C]-Mannitol and transcellular marker [^H]-Dexamethasone in PBS+ (pH 
7.4) under three different osmolarity (70，280 and 560 mOsm) conditions were also 
evaluated and compared. 
2.3.4 Inter-passage variation 
The inter-passage variation of Calu-3 cell line model was examined by 
comparing TEER and permeabilities of the paracellular marker ['"^C]-Mannitol and 
transcellular marker [^H] -Dexamethasone across the cell monolayers among the 




2.3.5 Statistical analysis 
All data were reported as mean 土 SD. Statistical significant difference 
between two groups was evaluated by Student's t-test. Statistical significant 
difference among more than two groups was evaluated by one-way ANOVA. A 
/7<0.05 was considered significant for all tests. 
2.4 Results and discussions 
2.4.1 Cell culture 
As reported previously, the Calu-3 cell line for permeation model was cultured 
under an air-interfaced condition on the Transwell inserts in the current study. 
Grainger et al. (2006) evaluated the effect of air-interfaced culture (AIC) and 
liquid-covered culture (LCC) on the morphology and permeability of Calu-3 cell 
monolayer. They found that the Calu-3 cells cultured using AIC generated a 
monolayer that is more morphologically representative of the airway epithelium 
than cells cultured using LCC. 
Transwell® inserts were all coated with collagen before seeding the Calu-3 
cells. It was found that collagen coated support materials could increase cell 
attachment and proliferation since collagen is a part of the lamina propria, which is 
a thin layer of loose connective tissue lying beneath the epithelium and constitutes 
the mucosa together with the epithelium (Werner et a l , 1995). 
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2.4.2 Cytotoxicity studies by MTS/PES assay 
2.4.2.1 Optimization of MTS/PES assay for the initial cell seeding 
density and the incubation time 
The relationships between the optical density (OD) of each well and the initial 
seeding densities of Calu-3 cells at an incubation time of 24 or 48 h are shown in 
Figure 2.1. The initial cell seeding densities ranging from 1x10^ to 1x10)4 cells/well 
showed linear correlation to OD values at both 24 and 48 h incubations. A drop of 
OD was observed when initial cell seeding density was higher than 5x10"^ cells/well. 
Since the OD value corresponding to an initial cell seeding density of 5x10^ 
cells/well was in the middle of the linear range, such seeding density was chosen as 
the initial cell seeding density for the following cytotoxicity study. Within the 
linear range, the OD values obtained after 48 h incubation were higher than those 
measured after 24 h incubation, and the linearity was also better when the Calu-3 
cells were incubated for 48 h (Figure 2.1，B). Based on the above findings, an 
initial cell seeding density of 5000 cells/well and an incubation time of 48 h would 
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Figure 2.1 The corrected optical density (OD) as a function of initial seeding density 
of Calu-3 cells by MTS/PES assay at an incubation time of 24 h or 48 h. The data 
are expressed as Mean 士 SD，n=4. The corrected OD values were calculated as the 




2.4.2.2 Cytotoxicity studies of non-physiological pH and osmolarity 
on Calu-3 cells by MTS/PES assay 
Effect of non-physiological pH on Calu-3 cells is shown in Figure 2.2. Only 
when the pH ranged from 6.0 to 9.0，the relative activity of the Calu-3 cells could 
reach 80% or above. The relative activity of Calu-3 cells quickly declined to 13% 
when the pH decreased to 4.0. 
Figure 2.3 showed that at the osmolarity range 70 to 1120 mOsm, the relative 
activity of the Calu-3 cells could reach 80% or above. However, when the 
osmolarity was less than 70 mOsm, the relative activity of Calu-3 cells decreased 
significantly. 
Therefore, only the pH and osmolarity at which the relative activity of Calu-3 
cells is above 80% would be employed in the following studies (Wang, 2005). 
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Figure 2.2 The relative activity of Calu-3 cells at different pH levels evaluated by 
MTS/PES assay. The data are expressed as Mean 土 SD, n=4. 
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Figure 2.3 The relative activity of Calu-3 cells in PBS with different osmolarities 
evaluated by MTS/PES assay. The data are expressed as Mean 士 SD，n=4. 
2.4.3 Integrity of Calu-3 cell monolayers 
In order to monitor the integrity of Calu-3 cell monolayers, two most popular 
methods were employed including measuring the TEER and determining the 
permeabilities of both paracellular and transcellular marker compounds. These are 
commonly used methods for evaluating the integrity of cell culture models for 
permeation studies, and have been previously applied to evaluation of the integrity 
of MDCK epithelial cell monolayer (Cho et al., 1989)，Caco-2 cell line model 
(Anderberg et al., 1993), HO-l-u-1 cell line model (Wang et al., 2007), primary 
cultures of human nasal epithelium (Yoo et al., 2003) as well as Calu-3 cell 
monolayer (Mathias et al., 2002). In addition, according to the literature (Ohwaki et 
al., 1985, 1987，1989; Vora et al.，1993; Dua et al•，1997; Olivier et al.，2001), 
non-isoosmotic solutions may cause the nasal epithelial cells to shrink or swell and 
thus affect the barrier function of the nasal epithelium. Therefore, the effect of 
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osmolarity on the integrity of Calu-3 cell monolayers was also investigated. 
2.4.3.1 Transepithelial electrical resistance (TEER) 
TEER reflects the cell monolayer's resistance to diffusional flow of ions, 
which can indicate the barrier function of the cell monolayer. When the TEER of 
the Calu-3 cell monolayers was determined at different time in culture (Figure 2.4)， 
it was observed that the TEER was very low (< 200 during the first 9 days 
of culture, which implies that the cells on the Transwell® inserts did not reach 
confluence. During the following 4 or 5 days, the TEER increased dramatically and 
reached the maximal value of 977.54+199.09 After day 15 of culture, the 
TEER started to drop gradually. 
It was noticed that significant inter-laboratory differences in the maximal 
TEER value can be observed when comparing literature reported TEER values of 
the Calu-3 cell line model. Foster et al. (2000) reported that the maximal TEER 
value of the Calu-3 cell model was around 600 Q*cm^ (remained between day 10 
and day 14 of culture), whereas the maximal TEER value was approximately 300 
(remained between day 5 and day 17 of culture) according to Grainger et al. 
(2006). In the third study, however, a maximal TEER value over 1000 was 
observed in the Calu-3 cell line model (remained between day 8 and day 20 of 
culture) (Mathias et a l , 2002). This is most likely due to differences in the culture 
conditions (Mathias et al., 2002; Florea et a l , 2003). 
According to our preliminary experiment, the recoveries of tested compounds 
(especially those permeate mainly through transcellular passive diffusion) obtained 
in Calu-3 cell monolayers cultured for more than 23 days were significantly lower 
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than that obtained in Calu-3 cell monolayers with culturing days between 15 and 21. 
It is expected that the greater cell density of the cell monolayers after longer culture 
might lead to higher cellular uptake of the compounds in the cell monolayers. 
Based on the above results, the optimal condition for Calu-3 cell monolayers 
for the permeation studies appeared to be between 15 and 21 days of culture with 
TEER greater than 500 in the present study (Foster et al., 2000; Mathias et 
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Figure 2.4 Transepithelial electrical resistance (TEER) across Calu-3 cell monolayers 
at different time in culture. The data are expressed as Mean 士 SD, n=12. 
2.4.3.2 Permeabilities of marker compounds 
2.4.3.2.1 Cytotoxicity of marker compounds by MTS/PES assay 
The objective for the cytotoxicity study is to control the drug concentration for 
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permeation studies below the toxic concentration. Due to the high sensitivity of the 
radioactive assay, the radiolabelled markers (["q-Mamiitol，[^"^CJ-PEG 4000， 
[^H]-Dexamethasone, [^H]-Testosterone and [^H]-water) were loaded onto the 
Calu-3 cell line model with very low concentrations. Therefore, cytotoxicity studies 
of these markers were not necessary. Only propranolol was studied for its cytotoxic 
effect on Calu-3 cells by MTS/PES assay (shown in Figure 2.5). The results 
showed that the relative activity of Calu-3 cells maintained to be greater than 80% 
after 2 hour incubations with propranolol concentrations lower than 5x10"^ M. 
Therefore, the concentration of propranolol employed in the following permeation 
study (1x10-4 M) should not significantly affect the integrity of Calu-3 cells during 
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Figure 2.5 Cytotoxic effect of propranolol on Calu-3 cells by MTS/PES assay. 
The data are expressed as Mean 士 SD, n=4. 
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2.4.3.2.2 Permeabilities of markers 
The apparent permeability coefficients (Papp) of the six marker compounds 
across the Calu-3 cell line model are shown in Table 2.1. ['"^C]-Mannitol and 
[14c]-PEG 4000 were commonly used as paracellular markers (Pezron et al., 2002; 
Wadell et a l , 2003). They are hydrophilic molecules that transport across the cell 
monolayers through the paracellular route. [^H]-Dexamethasone, [^H]-Testosterone 
and propranolol were usually used as transcellular markers (Nielsen et al., 2000; 
Mathias et al., 2002; Wang, 2005). These compounds permeate through the cell 
monolayers quickly by transcellular pathway because of their lipophilicity. Tritiated 
water was also used as a marker, and was expected to transport across the cell 
monolayer freely (Nielsen et al., 2000). Therefore, their permeabilities were 
predicted to be in the following order: water > transcellular markers > paracellular 
markers. The experimental results of the rank order for permeabilities were 
consistent with the above prediction. In addition, the recoveries of the transcellular 
markers were lower than those of the paracellular markers, probably due to the 
higher cellular uptake of the transcellular markers than that of the paracellular 
markers by Calu-3 cell monolayers. 
The comparison of the Papp values of mannitol and dexamethasone obtained in 
current study with those reported in previous literature (Mathias et a l , 2002) is 
shown in Figure 2.6. The results from the current study seem to be comparable to 
those published before, indicating that the current developed Calu-3 cell line model 
is similar to those developed in other labs. 
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Table 2.1 Apparent permeability coefficients (Papp) of the six marker compounds 
across Calu-3 cell line model (n=3 or 4). 
Marker compounds Papp (xlO'^cm/s) Recovery (%) 
Mannitol 1.14±0.11 92 士 3 
PEG 4000 2.57 ±0.21 94 ± 2 
Dexamethasone 64.81 ±2.68 8 6 ± 4 
Testosterone 205.01 ±9.41 73 ± 3 
Propranolol 227.27±5.50 91 土 2 
H2O 398.07 ±57.62 93 土 3 
Mannitol Dexamethasone 
2 100 
I 1.5 + I 8 � ‘ ^ ~ ~ 
,�:[i 11 
Ours Reported Ours Reported 
Figure 2.6 Comparison of the Papp of mannitol and dexamethasone obtained in this 
laboratory with the reported data (Mathias et al., 2002). 
2.4.3.3 Effect of osmolarity on the Calu-3 cell monolayer 
Figure 2.7 demonstrates the effect of osmolarity on the TEER of Calu-3 cell 
line model. The effect of osmolarity on the Papp of paracellular marker 
[14c]-Mannitol and transcellular marker [^H]-Dexamethasone across Calu-3 cell 
monolayers is shown in Figure 2.8. 
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The results indicated that the TEER of Calu-3 cell monolayers dropped 
significantly after a 2 hour incubation with a hypoosmotic solution (70 mOsm), 
while the isosmotic (280 mOsm) and hyperosmotic (560 mOsm) solutions showed 
little influence on the TEER of the cell monolayer. Papp of the paracellular marker 
mannitol was also significantly enhanced by the hypoosmotic solution, whereas the 
Papp of the transcellular marker dexamethasone was similar under the three different 
osmolarities. Thus, it could be concluded that hypoosmolarity may alter the 
paracellular pathway of the Calu-3 cell line model. Our finding is consistent with 
what was reported by Olivier et al. (2001) in rat in situ nasal model. They found 
that hypoosmolarity could enhance the nasal absorption of ionized midazolam, 
which permeates the nasal mucosa through the paracellular pathway. 
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Figure 2.7 TEER of Calu-3 cell line model before and after a 2 hour incubation 
with hypoosmotic (70 mOsm), isosmotic (280 mOsm) and hyperosmotic (560 
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Figure 2.8 Effect of osmolarity on the Papp of paracellular marker [^"^CJ-Mannitol and 
transcellular marker [^H]-Dexamethasone across Calu-3 cell monolayers. The data are 
expressed as Mean 士 SD，n=3 or 4. *:p<0.05, ***:pO.OOl. 
2.4.4 Inter-passage variation 
The TEER and Papp of the paracellular marker ['"^C]-Mannitol and transcellular 
marker [^H]-Dexamethasone across the Calu-3 cell monolayers with cell passage 
numbers of 21, 23 and 25 are present in Table 2.2. Data analysis by One-way 
ANOVA showed that there was no statistically significant difference in TEER, Pgpp 
values and Recovery percentage among the three batches of Calu-3 cell monolayers. 
Such results suggested that the characteristics of Calu-3 cell line were stable within 
cell passages 21 to 25. Therefore, in the following studies, Calu-3 cells with 
passage number from 21 to 25 would be used in order to obtain consistent data 
from different cell batches. 
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Table 2.2 TEER and Papp of the paracellular marker ['"^CJ-Mannitol and transcellular 
marker [^H]-Dexamethasone across the Calu-3 cell monolayers with cell passage 
numbers of 21，23 and 25. 
Passage TEER [^^C]-Mannitol (n=3 or 4) [^H]-Dexamethasone (n=3 or 4) 
number (U-cm^) (n=8) > R e c o v e r y ^ Recovery 
( x l Q - W s ) (%) ( x l O ' W s ) (%) 
21 699±170 1.14±0.11 9 2 ± 3 64.81±2.68 86 士 4 
23 7 0 3 ± 3 5 1.19±0.16 9 0 ± 1 65.65±3.89 8 4 ± 4 
25 6 4 2 ± 2 4 1.33±0.12 9 4 ± 5 60.84±3.00 81 ± 2 
2.5 Conclusion 
The optimal culture condition for Calu-3 cell monolayers for the permeation 
studies appeared to be between 15 and 21 days of culture based on TEER greater 
than 500 Q-cm^. An optimized MTS/PES assay was used to monitor the potential 
cytotoxicity of permeation marker compounds, non-physiological pH and various 
osmolality conditions to make sure that the permeation studies were conducted 
under non-cytotoxic conditions. The apparent permeability coefficients (Papp) of the 
marker compounds ranged from 1.14 ±0.11 x l O ' W s to 398.07 ±57 .62 x l O ' W s , 
with Papp values of paracellular markers < transcellular markers < tritiated water as 
expected. It was found that hypoosmotic solutions not only significantly decreased 
the TEER of the Calu-3 cell monolayers but also significantly enhanced the 
permeability of the paracellular marker [i4c]-Mannitol but not the transcellular 
marker [^H]-Dexamethasone. No significant inter-passage variation was found with 
the cell passage number ranged from 21 to 25. The above validation results indicate 




potentially be useful as an in vitro model for nasal drug permeation screening. 




Permeation studies of selected drug candidates using the 
Calu-3 cell line model 
3.1 Introduction 
To further verify the ability of Calu-3 cell line ifor nasal drug delivery 
screening, four selected drug candidates with potential therapeutic advantage of 
nasal delivery will be investigated using the Calu-3 cell line model in the current 
study. For selection of such drug candidates, the required drug characteristics 
included: 1) Application for treatment of diseases that require quick onset of action; 
2) Low therapeutic dose, which is essential for nasal drug delivery due to the small 
volume of the nasal cavity; 3) Appropriate nasal absorption properties, such as low 
molecular weight and moderate lipophilicity. As summarized in section 1.2, all the 
four drug candidates chosen in the current study are useful for either rapid 
analgesic therapy or treatment of angina cordis. In addition, their therapeutic doses 
are all less than 30 mg daily. Moreover, they are all small molecules with 
appropriate log P (between 0.96 and 3.7). 
In this chapter, the permeability of each drug candidate across the Calu-3 cell 
line model will be determined and the factors (including concentration, pH and 
osmolarity) that may affect their permeabilities across the Calu-3 cell line model 
will also be evaluated. In addition, permeation studies of these drug candidates at 
different pHs will be carried out in the artificial membrane model, and the results 
will be compared with those obtained from the Calu-3 cell line model. Finally, the 





Rizatriptan benzoate, lomoxicam and meloxicam were obtained from Iffect 
Chemphar Co., Ltd (China). Nebivolol hydrochloride was provided by Hwasun 
Biotechnology Co., Ltd (China). Phosphate buffered saline tablet and hexadecane 
were supplied by Sigma-Aldrich Co. (USA). n-Hexane was purchased from Tedia 
Inc (USA). CellTiter 96® AQueous One Solution Cell Proliferation Assay was 
provided by Promega Corporation (USA). Acetonitrile (ACN) was obtained from 
Lab Scan Asia Co. (Thailand). Triethylamine (TEA) was purchased from BDH 
Laboratory Supplies (England). Other chemical reagents used were at least of 
analytical grade. 
3.2.2 Materials for cell culture 
The Calu-3 cell line and other cell culture materials were obtained as 
described in section 2.2.2. 
3.2.3 Instruments 
The instruments used for this part of experiment consisted of a Benchmark 
Microplate Reader from Bio-Rad Laboratories Inc. (USA), a Leica Precision 
Inverted Microscope from Leica Co. (Germany), and an epithelial voltohmmeter 
from World Precision Instruments (USA). For drug concentration determination, an 
HPLC system consisting of a Waters 2695 solvent delivery module, a Waters 996 
photodiode array (PDA) detector and a BDS Cig reversed phase column (4.6 mm 





3.3.1 HPLC assay development and validation for the drug 
candidates 
The related HPLC injection volume, mobile phases and UV detection 
wavelength for the four drug candidates are listed in Table 3.1. The flow rate was 
set at 1.0 ml/min. Validation of the developed HPLC methods was conducted by 
determining the intra-day, inter-day accuracy and precision at low, medium and 
high concentration levels. The precision was defined as the relative standard 
deviation (RSD) and the accuracy was the percentage difference of the determined 
concentration from the nominal value. The linearity of calibration curve was also 
examined. 
Table 3.1 Summary of HPLC assay conditions for the four drug candidates. 
Compounds Inject volume Isocratic Mobile Phase Wavelength of 
C i^l) UV detector (nm) 
Rizatriptan ^ 14% acetonitrile in 20mM NaH2P04 ^ 
buffer solution (0.5%TEA, pH 5.2) 
Meloxicam ^ 35% acetonitrile in 20mM NaH2P04 ^ 
buffer solution (pH 5.2) 
Lomoxicam 20 35% acetonitrile in 50mM NaAc ^ 
buffer solution (pH 5.8) 
Nebivolol ^ 50% acetonitrile in 20mM NaH2P04 
buffer solution (0.5%TEA, pH 3.0) 
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3.3.2 Stabilities of the drug candidates in loading solutions at 
different pHs 
The stabilities of the selected drugs in loading solutions were evaluated to 
make sure that the drug candidates were stable during the 2 hour permeation study 
across Calu-3 cell line model in HBSS (37�C) and during the 5 hour permeation 
study across the artificial membrane model in PBS (37�C). 
Rizatriptan, meloxicam and lomoxicam were dissolved in isoosmotic HBSS 
and PBS to obtain a concentration of IxlO""^ M. Nebivolol was dissolved in HBSS 
and PBS containing 1% DMSO to achieve a concentration of 5x10'^ M. The pHs of 
the drug solutions were adjusted to 6, 7, 8 and 9 by phosphoric acid or sodium 
hydroxide. The final HBSS and PBS solutions containing the selected drugs under 
different pHs were incubated in water bath (37°C) for 2 and 5 hours, respectively. 
Samples (ISO^il) were collected before and after the incubation followed by 
analyses by HPLC. 
3.3.3 Cell culture 
The methods for culturing Calu-3 cells and preparation of Calu-3 cell line 
model were as described in section 2.3.1. 
3.3.4 Cytotoxic effects of the drug candidates on Calu-3 cells by 
MTS/PES assay 
The methods for cytotoxicity studies of the drug candidates on Calu-3 cells 
were the same as described in section 2.3.3.2.1. The test solutions in this section 
included: rizatriptan dissolved in HBSS with concentrations ranging from 10"^  to 
10-2 M，meloxicam in HBSS with concentrations from 10"^  to 2x10"^ M, 
lomoxicam in HBSS with concentrations from 10"^  to 2x10"^ M，nebivolol 
-dissolved in HBSS containing 1% co-solvent DMSO to concentrations ranging 
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from 10-6 to 2x10"^ M, and DMSO in HBSS to a concentration range of 1% to 8% 
(v/v). For nebivolol, instead of using HBSS as the negative control like other test 
solutions, 1% DMSO in HBSS was employed as the negative control, since the 
nebivolol test solutions in the current study utilized 1% DMSO in HBSS as solvent. 
3.3.5 Permeation studies of drug candidates using Calu-3 cell line 
model 
3.3.5.1 Effect of concentration on the permeabilities of drug 
candidates across Calu-3 cell line model 
Rizatriptan was dissolved in HBSS (pH 7.4，280 mOsm) to three different 
concentrations of 5x10"^ 1x10'^ and 5x10"^ M. Meloxicam and lomoxicam were 
dissolved in HBSS (pH 7.4, 280 mOsm) to three different concentrations of 5x1 
1x10-4 and 2x10-4 M. Nebivolol was dissolved in HBSS (pH 7.4, 280 mOsm) 
containing 1% DMSO to three different concentrations of 1x10"^ 2x10"^ and 
5x10-5 M. 
On the day of experiment, the medium in the basolateral chamber of the 
Transwell® was removed. After washing with 37�C HBSS, the cell monolayers 
were equilibrated in HBSS (0.2 ml in apical chamber, 0.8 ml in basolateral chamber) 
at 37°C for 10 min. Then, the HBSS in the apical chamber was aspirated and 0.2 ml 
of pre-warmed test solutions (37°C) were added to the apical chamber. Samples 
(100|al) were taken from the basolateral chamber at various time intervals, and the 
same amount of 37°C HBSS was supplemented immediately after every sampling 
to maintain the constant volume of the fluid in receiver chamber. At the end of the 
experiment, 100 |il samples were taken from both the apical and basolateral 
chambers to calculate the recovery of the tested compound according to equation 
2.1 (see section 2.3.3.2.2). The samples were analyzed by HPLC (as described in 
section 3.3.1) and the apparent permeability coefficient was calculated according to 
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equation 2.2 (see section 2.3.3.2.2). 
3.3.5.2 Effect of pH on the permeabilities of drug candidates across 
Calu-3 cell line model 
Rizatriptan, meloxicam and lomoxicam were dissolved in HBSS to a 
concentration of 5x10"^ IxlO"^ and 1x10"^ M, respectively. The pHs of drug 
loading solutions were adjusted to 6, 7，8 and 9 using phosphoric acid or sodium 
hydroxide before they were loaded to the apical side of the Calu-3 monolayers. The 
permeation studies were carried out at 37°C according to the method described in 
section 3.3.5.1. 
3.3.5.3 Effect of osmolarity on the permeabilities of drug 
candidates across Calu-3 cell line model 
Rizatriptan was dissolved in PBS+ with three different osmolarities (70, 280 
and 560 mOsm). The permeation studies were carried out at 37°C according to the 
method described in section 3.3.5.1. 
3.3.6 Permeation studies of drug candidates in artificial membrane 
model at different pHs 
Rizatriptan, meloxicam and lomoxicam were dissolved in PBS to a 
concentration of 1x10'^ 1x10-4 and 1x10"^ M, respectively. Nebivolol was 
dissolved in PBS containing 1% DMSO to a concentration of 5x10"^ M. The pHs of 
drug solutions were adjusted to 6, 7, 8 and 9 using phosphoric acid or sodium 
hydroxide. 
The artificial membrane model used in the present study comprised the 
Multiscreen® Permeability plate (polycarbonate support, 0.45|xm, Millipore, USA) 
and the MultiScreen® Acceptor plate (100% PTFE (Polytetrafluoroethylene), 
7 3 
Chapter Three 
Millipore, USA). Before permeation studies, the polycarbonate supports of 
Multiscreen® Permeability plate were coated with a hexadecane layer by adding 30 
III of 5% hexadecane in n-hexane to each well and putting the plate in the fume 
hood for 2 h to enable the hexane to evaporate. Subsequently, 150 \i\ of pre-warmed 
test solution (37°C) mentioned above was added into the wells of MultiScreen® 
Permeability plate, called donor chambers, which was connected to the 
Multiscreen® Acceptor plate that was prefilled with 250 |il of 37�C PBS (or PBS 
containing 1% DMSO for permeation study of nebivolol) in each well, called 
acceptor chamber. This sandwich-like structure was incubated at 37°C for 5 h, and 
was then disassembled. Samples were withdrawn from both the donor chambers 
and the acceptor chambers after the 5 hour incubation, and were analyzed by 
HPLC. 
According to the instruction from the supplier of MultiScreen®, the Papp 
(cm/sec) of a compound across such artificial membrane model was calculated 
according to the following equation: 
Papp = C X - ln ( l - [drUg]acceptor ! [drUg]equilibrium) ( 3 . 1 ) 
Where C = VdxVa / [(VD+VA)xAreaxtime]，[drug]acceptor is the drug 
concentration (mol/ml) in the acceptor chamber at the end of the permeation study 
and [drug]equiiibrium = [drugjioadingXVo / (VD+VA). "VD" (ml) is the volume in the 
donor chamber, "Va" (ml) is the volume in the acceptor chamber, "[drug]loading" is 
the initial loading concentration of the drug (mol/ml) in the donor chamber, "time" 
(sec) is the duration of the drug permeation study, and “Area，，(cm^) is the 
"effective area" of the membrane, which is the surface area multiplied by the 
porosity ratio (20% for polycarbonate). 
3.3.7 Correlation of the permeabilities of drug candidates between 
Calu-3 cell line model and artificial membrane model 
The correlation of the permeabilities of the four drug candidates at different 
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pHs across Calu-3 cell line model and artificial membrane model was evaluated by 
calculating Pearson's correlation coefficient and examining the statistical 
significance of the correlation using SPSS 16.0 (SPSS Inc, USA). 
3.3.8 Statistical analysis 
All data were reported as mean 士 SD. Statistical significant difference between 
two groups was evaluated by Student's t-test. Statistical significant difference 
among more than two groups was evaluated by one-way ANOVA. A /?<0.05 was 
considered significant for all tests. 
3.4 Results and discussions 
3.4.1 HPLC methods for the drug candidates 
The calibration curves of the four drug candidates were linear over the studied 
concentration ranges. The intra-day, inter-day accuracy and precision of the assays 
for the four drugs at low, medium and high concentrations were all within 15% 
(Table 3.2). These results indicated that the developed HPLC methods were 
suitable for the sample analysis of the current study. 
3.4.2 Stabilities of the drug candidates in loading solutions at 
different pHs 
Since the drug candidates prepared in loading solutions may undergo 
degradation during the permeation studies, which may further alter their true Papp, 
the stabilities of the drug candidates in loading solutions were evaluated prior to the 
permeation studies. As shown in Figure 3.1 and 3.2, the drug candidates were all 
stable under the conditions for permeation studies across Calu-3 cell line model and 
artificial membrane model. 
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3.4.3 Cytotoxic effects of the drug candidates on Calu-3 cells by 
MTS/PES assay 
The purpose for the cytotoxicity study is to make sure the loading drug 
concentrations for permeation studies would not be toxic to the Calu-3 cells. The 
cytotoxic effects of the drug candidates and the co-solvent DMSO, which was used 
to aid solubilization of nebivolol, on Calu-3 cells by MTS/PES assay are shown in 
Figure 3.3 and 3.4，respectively. The highest concentrations of rizatriptan (5x10"^ 
M), meloxicam (2x10"^ M), lomoxicam (2x10"^ M), nebivolol (5x10.5 M) and 
DMSO (1%) employed in the further permeation studies were all within the ranges 
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Figure 3.4 Cytotoxic effect of DMSO on Calu-3 cells by MTS/PES assay. The 
data are expressed as Mean 士 SD，n=4. 
3.4.4 Permeation studies of drug candidates in Calu-3 cell line 
model 
3.4.4.1 Effect of concentration on the permeabilities of drug 
candidates across Calu-3 cell line model 
To determine whether the four drug candidates permeate the Calu-3 cell 
monolayers through passive diffusion or active transport, the permeabilities of the 
drug candidates at three different loading concentrations were investigated (Figure 
3.5 and Table 3.3). Although the permeability of rizatriptan seemed to increase at 
the higher concentration, the Papp values of rizatriptan were in the range of 10"^cm/s, 
which is comparable to most of the paracellular markers (Pezron et a l , 2002; 
Mathias et al., 2002; Wadell et al., 2003) and much less than that of meloxicam and 
lomoxicam (Papp over lO'^cm/s). Therefore，it may be concluded that rizatriptan 
permeates the Calu-3 cell monolayers mainly via paracellular passive diffusion. For 
meloxicam and lomoxicam, Papp values were comparable among the 3 different 
loading concentrations. Therefore, it seems that passive diffusion was the main 
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pathway for rizatriptan, meloxicam and lomoxicam to permeate across the Calu-3 
cell line model. 
Comparing with the other three candidates, nebivolol is the most lipophilic 
with a Log P of 3.7 (as shown in Table 1.1)，which led to a very low solubility (<8 
|ig/ml) and an extraordinarily high cellular uptake in the Calu-3 cell line model 
(recovery <15%). Such high cellular uptake of nebivolol resulted in a high cellular 
toxicity (as shown in section 3.4.3) and low permeability in the Calu-3 cell line 
model. Within the non-toxic concentration range, the Papp of nebivolol could not be 
determined at the 2 lower loading concentrations, and the Papp obtained at the 
higher concentration was very low (6.26 土 0.24 x 10"^cm/s). In view of these results, 





















































































































































































































































Table 3.3 Permeabilities (Papp) and recoveries of the four drug candidates across 
Calu-3 cell line model at 3 different loading concentrations (n=3 or 4). 
Compounds Loading Papp Recovery p (compare Papp) 
Cone. (|iM) ( x l O ' W s ) (%) (one-way ANOVA) 
Rizatriptan ^ 6.86 ±0.13 92 ± 1 500 vs. 1000 0.998 
1000 6.84 士 0.29 91 士 3 500 vs. 5000 <0.0005 
5000 9.95 士 0.49 88 士 3 1000 vs. 5000 <0.0005 
Meloxicam 50 176.14 ± 15.04 84 ± 5 50 vs. 100 0.488 
100 188.66 士 16.72 88 士 6 50 vs. 200 0.182 
200 196.60 士 12.61 96 士 5 “ 100 vs. 200 0.739 
Lomoxicam 50 146.85 ± 5.32 73 士 2 50 vs. 100 0 . 3 7 9 ^ 
100 140.42 士 6.12 77 士 4 50 vs. 200 0.883 
200 149.05 士 7.75 83 士 2 100 vs. 200 0.199 
Nebivolol 10 N ^ 6 ^ 2 NA^ N ^ 
20 N D ' 6 士 2 N A ' N A ' 
50 6.26 士 0.24 11 士 1 NA"" N A ' 
* ND: not detectable; NA: not applicable. 
3.4.4.2 Effect of pH on the permeabilities of drug candidates across 
Calu-3 cell line model 
The permeabilities of rizatriptan, meloxicam and lomoxicam across Calu-3 
cell line model at different pH levels are presented in Figure 3.6 and Table 3.4. As 
expected, the Papp of rizatriptan increased with the increase of pH, whereas the Papp 
of meloxicam and lomoxicam decreased when pH increased. 
The experimental results were consistent with the theoretical predictions based 
on the ionization of the drug candidates. Since these three drug candidates are all 
weak organic acids or bases, they exist in aqueous solutions in both ionized and 
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unionized forms. Unionized species of a drug are more lipophilic than ionized 
species, resulting in a better absorption for unionized species. The pH of a drug 
solution can affect the percentage of unionized species of a drug and thus affects its 
permeability. Rizatriptan is a weak base with a pKa of 9.49 (Table 1.1), so 
theoretically its permeability should increase when pH increases. Meloxicam and 
lomoxicam are weak acids, both with pKa of 4.50 (Table 1.1)，so theoretically their 
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Figure 3.6 Permeabilities (Papp) of rizatriptan, meloxicam and lomoxicam across 
Calu-3 cell line model at different pH levels. The data are expressed as Mean 士 
SD, n=3 or 4. 
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Table 3.4 Percentages of unionized species, permeabilities (Papp) and recoveries of 
rizatriptan, meloxicam and lomoxicam across Calu-3 cell line model at different pH 
levels (n=3 or 4). 
Compounds pH % Papp Recovery p (comparison of Papp) 
Unionized ( x l O " W s ) (%) (one-way ANOVA) 
Riza t r ip tan""6 ^ 3.84 + 0.46 ^ 
7 0.323 6.09 + 0.72 93 ± 4 \ 
8 3 135 7.21 ±0.89 9 0 ± 7 7 vs. 8 0.302 
9 0.001 
9 24 448 9.21 ±1.20 9 2 ± 5 
8 vs. 9 0.029 
Meloxicam 6 ^ 3 4 1 . 1 5 ± 3 1 . 9 8 9 2 ± 2 ^ ^ ^ ； ^ 
1 1-7-U-7 OA o . , -7 8 <0.0005 
7 0.315 232.17±7.30 8 7 ± 7 9 <0.0005 
8 0.032 175.87±9.90 8 5 ± 5 7 vs. 8 0.017 
9 0.002 
9 0 003 161.11±10.61 9 4 ± 2 
8 vs. 9 0.781 
Lomoxicam 6 3.065 256.72±14.02 7 3 ± 5 石 vs. 7 <0.0005 
7 0.315 178.99+15.09 75 + 3 9 二二 f 
8 0 032 164.36+11.14 78 + 6 7 vs. 8 0.440 
‘ 9 0.046 
9 0 003 150.55 土 12.76 77 土 5 
8 vs. 9 0.486 
3.4.4.3 Effect of osmolarity on the permeabilities of drug 
candidates across Calu-3 cell line model 
Since the Papp values of rizatriptan across Calu-3 cell line model were at the 
same order of magnitude cm/s) as the Papp values of paracellular markers 
[i4c]-Mannitol and [^ "^CJ-PEG 4000 (Table 2.1), it can be concluded that rizatriptan 
permeates the Calu-3 cell line model mainly through the paracellular way. 
Meanwhile, meloxicam and lomoxicam seem to permeate the Calu-3 cell line 
model mostly through the transcellular pathway, since their Papp values were 
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comparable to the Papp values of transcellular markers [^H]-Testosterone and 
propranolol (Table 2.1). 
According to our previous results (in section 2.4.3.3) and others (Olivier et al., 
2001), hypoosmolarity might enhance permeability of compounds that permeate 
paracellularly. Therefore, rizatriptan but not meloxicam or lomoxicam was studied 
for the effect of osmolarity on its permeability across the Calu-3 cell line model 
(Figure 3.7). The result showed that the permeability of rizatriptan was 
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Figure 3.7 Permeabilities (Papp) of rizatriptan across Calu-3 cell line model 
under different osmolarities. The data are expressed as Mean 士 SD, n=4. 
***:p<0.001. 
3.4.5 Permeation studies of drug candidates in artificial membrane 
model at different pHs 
Unlike Calu-3 cell line model, the concentration and osmolarity factors can 
hardly affect the permeabilities of compounds across the artificial membrane model 
due to its non-biological nature. Therefore, only the permeabilities of drug 
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candidates at different pHs were studied in the artificial membrane model (Figure 
3.8 and Table 3.5). Since rizatriptan and nebivolol are weak bases, their Papp 
increased with the increase of pH. Meloxicam and lomoxicam are weak acids, so 
their Papp decreased when pH increased. These results from the artificial membrane 
model were similar to that obtained from the Calu-3 cell line model, but with more 
dramatic changes of Papp among different pHs. It may also be noted that even in the 
artificial membrane model, the recoveries of nebivolol were very low, especially at 
higher pHs where the percentages of unionized species of nebivolol are higher, 





































































































































































































































































Table 3.5 Percentages of unionized species, permeabilities (Papp) and recoveries of the four 
drug candidates across artificial membrane model at different pH levels (n=4). 
Compounds pH % Papp Recovery p (comparison of Papp) 
Unionized ( x l O " W s ) (%) (one-way ANOVA) 
R i z a t r i p t a n 6 ^ 0.09±0.01 ^ ^ ^ 0.6O6 
7 0.323 0.68±0.03 105±7 9 二 J : = 
8 3.135 3.59 + 0.27 102±3 7 vs. 8 <0.0005 
9 <0.0005 
9 24 448 18.09±1.30 100±1 
“ 8 vs. 9 <0.0005 
M e l o x i c a m 6 ^ 1 5 5 0 . 9 3 ± 1 0 9 . 9 4 ^ ^ ^ < o . _ 5 
7 0.315 192.90± 118.13 99±3 9 2：0005 
8 0.032 21.66 + 2.93 100±2 7 vs. 8 0.047 
“ 9 0.035 
9 0 003 11.90±1.02 101±0 
‘ 8 vs. 9 0.998 
L o m o x i c a m 6 ^ 980.77 + 9.82 102 + 3 ^ ^ < o . _ 5 
7 0.315 250.01+7.34 9 9 + 1 J T o m o l 
8 0 032 36.67±1.91 100±1 7 vs. 8 <0.0005 
‘ 9 <0.0005 
9 0 003 9.75 ±1.09 101 ± 1 
. 8 vs. 9 <0.0005 
Nebivolol 6 ^ ^ 12.73 + 3.30 7 9 ± 5 “ “ T T T ^ 
u . … 6 vs. 7 <0.0005 
7 2.190 263.08 士 26.79 66 + 5 ^ 二 JJ; 
8 18.292 711.07±56.23 5 7 ± 7 7 vs. 8 <0.0005 
9 <0.0005 
9 69.124 986.81 ±37.04 5 6 ± 4 
8 vs. 9 <0.0005 
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3.4.6 Correlation of the permeabilities of drug candidates between 
Calu-3 cell line model and the artificial membrane model 
The scatter plot of Papp of the four drug candidates in Calu-3 cell line model vs. 
their Papp in artificial membrane model is presented in Figure 3.9. The SPSS output 
showed that the Pearson's correlation coefficient (R) was 0.730，indicating a trend 
of positive correlation between the two models. In addition, the statistical analysis 
by SPSS indicated that this correlation was highly statistically significant {p 
<0.0005). These results indicate that Calu-3 cell line model can be used as an in 
vitro biological model for nasal drug permeation screening. Since it is based on 
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Figure 3.9 Correlation of permeabilities of the four drug candidates between Calu-3 
cell line model and artificial membrane model. 
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3.5 Selection of drug candidate for further in vivo studies 
After the in vitro permeation studies, the most promising drug candidate 
would be selected for further in vivo studies. Rizatriptan was excluded for its low 
permeability, and nebivolol was given up for both its low permeability and 
solubility. A comparison of the pharmacokinetics and stability data between the two 
analgesics meloxicam and lomoxicam was conducted to distinguish a better 
candidate for in vivo animal study. 
The Tmax of meloxicam was reported to be 6-11 h after oral administration 
(Tiirck et al., 1996; Davies et al., 1999), while that of lomoxicam was 0.5-3 h 
(Hitzenberger et al., 1990; Olkkola et al., 1994). Hence, there is a plenty of room 
for improvement in the onset of action for meloxicam, but not lomoxicam. In terms 
of stability, lomoxicam was reported to be unstable in solution and would form a 
large number of degradation products within weeks on standing at room 
temperature (Penkler et al., 1996). There are no reports on the stability of 
meloxicam. Nevertheless, our preliminary experiment showed that meloxicam was 
stable in PBS (pH 7.4) after 24 h at room temperature (remaining percentage = 
100.44 ±1.79, n=3), whereas the remaining percentage of lomoxicam under the 
same condition was 87.90 ±2.65 (n=3). Therefore, it can be concluded that 
meloxicam is more stable than lomoxicam in solution. The potential instability of 
lomoxicam may bring difficulties in its future aqueous formulation development 
for nasal delivery. 
As a result, meloxicam was selected to be the most appropriate drug candidate 
for nasal delivery for systemic purpose. Its nasal absorption studies would be 
carried out in rats. 
3.6 Conclusion 
In this Chapter, the stabilities of the four drug candidates in the loading 
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solutions were investigated and all the candidates were found to be quite stable 
under the conditions for permeation studies across Calu-3 cell line model and 
artificial membrane model. The MTS/PES assay was used for determining the 
cytotoxic effects of the drug candidates on Calu-3 cells to make sure that the 
permeation studies would be carried out within the non-cytotoxic concentration 
ranges. It was found that passive diffusion was the main transport pathway for 
rizatriptan, meloxicam and lomoxicam in permeating through the Calu-3 cell line 
model and their permeabilities were pH dependent. According to their Papp values, 
it could be concluded that rizatriptan permeated Calu-3 cell monolayers mainly 
through the paracellular passive diffusion route, while meloxicam and lomoxicam 
permeated mostly via the transcellular passive diffusion pathway. Hypoosmolarity 
enhanced the permeability of paracellularly transported drug rizatriptan. Since 
nebivolol showed low solubility, high cellular uptake, high cytotoxicity and low 
permeability in Calu-3 cell line model, no further investigation of it was carried out 
in the Calu-3 cell line model. A good correlation was observed for the 
permeabilities of drug candidates under different pHs between the Calu-3 cell line 
model and the artificial membrane model. After the comparison of permeability, 
pharmacokinetics and stability data, meloxicam was selected as the most promising 




In vivo absorption studies of the most promising drug 
candidate 
4.1 Introduction 
Meloxicam is a nonsteroidal anti-inflammatory, drug (NSAID) which 
decreases prostaglandin synthesis by inhibiting cyclo-oxygenase (COX). It exhibits 
analgesic, antipyretic and anti-inflammatory effects. Meloxicam has been shown, 
especially at its low therapeutic dose, to selectively inhibit COX-2 over COX-1 
(Tiirck et al., 1996). As a result, it significantly decreases symptoms of pain with a 
low incidence of gastrointestinal side effects. At present, oral and parenteral 
formulations are the only commercially available dosage forms in the market. 
However, oral meloxicam were reported to reach Cmax 6-11 h after administration 
(Tiirck et al., 1996; Davies et al., 1999), which makes it not applicable for 
situations requiring quick onset of action of the drug, such as acute mechanical 
lower back pain, sciatica and acute flares of osteoarthritis. Intramuscular or 
subcutaneous administration of meloxicam can achieve much faster onset of action, 
but they are inconvenient and not suitable for self medication. 
According to the permeation studies in Chapter 3, meloxicam was highly 
permeable in Calu-3 cell line model, with Papp values in the range of 10"^  cm/s. This 
result indicates that meloxicam is likely to achieve a quick onset of action via the 
convenient and non-invasive nasal delivery. 
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The objective of the current study is to perform the in vivo nasal absorption 
studies of meloxicam in rat model, so as to verify the above prediction made from 
the in vitro Calu-3 cell line model. The pharmacokinetics profiles of meloxicam via 




Meloxicam and lomoxicam (used as internal standard) were obtained from 
Iffect Chemphar Co., Ltd (China). Phosphate buffered saline tablet and sodium 
hydroxide were supplied by Sigma-Aldrich Co. (USA). Ethyl acetate and 
acetonitrile (ACN) were purchased from Lab Scan Asia Co. (Thailand). Tween 80 
was provided by Wing Hing Chemical Co., Ltd (Hong Kong). Sodium dihydrogen 
phosphate was obtained from BDH chemicals Ltd (England). Phosphoric acid 
(85%) was purchased from Merck (Germany). Other chemical reagents used were 
at least of analytical grade. 
4.2.2 Instruments 
The HPLC system consists of a Waters 2695 solvent delivery module, a 
Waters 996 photodiode array (PDA) detector and a BDS Cig reversed phase column 




4.3.1 HPLC conditions 
The mobile phase consisted of 25% acetonitrile and 75% 20mM NaH2P04 
buffer solution (pH 5.2). The flow rate was 1.0 ml/min, and the total running time 
was 15 min. The auto-sampler was set at 10�C. The wave-length of the UV detector 
was set at 364 nm for meloxicam and lomoxicam, the internal standard (IS). 
4.3.2 Preparation of standard solutions 
Stock solution of meloxicam (351.4 i^g/ml) was prepared by dissolving the 
appropriate amount of authentic meloxicam in 0.0IM NaOH. The working 
solutions of meloxicam were prepared by diluting the stock solution with deionized 
water to yield concentrations of 1.757，3.514，8.785, 17.57, 35.14, 87.85 and 175.7 
|ig/ml, respectively. 
The internal standard solution containing 371.8 |ig/ml of lomoxicam was 
prepared in 0.0IM NaOH. 
The samples for plasma standard calibration curves were prepared by spiking 
the blank rat plasma (100 with lOfil of the appropriate working solutions to 
yield the following concentrations of meloxicam: 0.1757, 0.3514, 0.8785, 1.757， 
3.514, 8.785, 17.57 and 35.14 |ig/ml, respectively. Specific quality control samples 
representing low, medium and high concentration were prepared at concentrations 
of 0.3514，3.514 and 35.14 \ig/m\ for meloxicam. 
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4.3.3 Calibration curves 
The plasma samples for standard curve were prepared as described in section 
4.3.2. Calibration curves were obtained by plotting the peak-area ratios of each 
analyte/IS vs. concentrations of each analyte in plasma. In order to avoid undue 
bias to the low concentrations of the standard curve by the high concentrations, a 
weight of 1/x^ (Miller et al., 1984) was applied to the calibration curves (GraphPad 
Prism 3.0, GraphPad software Inc., USA). 
4.3.4 Sample preparations 
In 100|il of plasma sample, 50 |il of IS was added followed by 100 |il of 10% 
H3PO4 to acidify the sample. The acidified mixture was then extracted with 1ml 
ethyl acetate by vortexing for 2 minutes. After centrifuging at 3000rpm for lOmin, 
the organic layer was collected and evaporated to dryness in a vacuum concentrator. 
The residue was reconstituted with 100 |al of 40% acetonitrile in 20mM NaH2P04 
buffer solution (pH 5.2). An aliquot of 20 |il was injected into the HPLC system for 
analysis. 
4.3.5 Validation of the assay method 
4.3.5.1 Specificity 
The specificity of the assay method was investigated by comparing the 
chromatogram of blank plasma samples from different rats with that of blank rat 
plasma spiked with standard solution and the rat plasma samples collected after 
nasal administration of meloxicam. 
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4.3.5.2 Precision and accuracy 
The intra-day precision and accuracy was determined within one day by 
analyzing five replicates quality control samples at concentrations of 0.3514, 3.514， 
and 35.14 p-g/ml. The inter-day precision and accuracy were determined on five 
separate days for the quality control samples. The precision was defined as the 
relative standard deviation (RSD) and the accuracy was the percentage difference 
of the determined concentration from the nominal value. 
4.3.5.3 Recovery 
Extraction recovery was calculated by comparing the peak areas of the 
extracted quality control samples with that of the unextracted standard solutions 
containing the equivalent amounts of analytes. 
4.3.5.4 Sensitivity 
The limit of detection (LOD) was defined as the lowest concentration of the 
drug resulting in a signal-to-noise ratio of 3:1. The limit of quantification (LOQ) 
was defined as the lowest concentration of the drug that can be determined with 
sufficient precision (less than 20%) and accuracy (-20% to 20%). 
4.3.5.5 Stability 
Freeze-thaw stability of the plasma samples was evaluated by exposing 
quality control samples to three freeze-thaw cycles before sample preparation. 
Stability of the plasma samples at room temperature was estimated by placing 
quality control samples at room temperature for 4 hours before sample prep扯ation. 
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The stability of the prepared samples in auto-sampler was evaluated by analyzing 
extracted quality control samples after being placed in the auto-sampler at 10°C for 
24 hours. 
4.3.6 Animals 
Male Sprague-Dawley rats weighting 220-240g were supplied by the 
laboratory Animal Services Center at the Chinese University of Hong Kong. The 
rats were housed in an air-conditioned room under a 12/12 hour light/dark cycle. 
The experiment was conducted after approval by Animal Ethics Committee of the 
Chinese University of Hong Kong. The rats were randomly grouped into 3 groups 
to receive different routes of administration of meloxicam with 7-8 rats in each 
group. 
For oral and intravenous administration, a light surgery of the rat was 
performed the day before the experiment. The rat was anesthetized with an 
intraperitoneal injection of a mixture containing 60 mg/kg ketamine and 6 mg/kg 
xylazine. For oral administration, the right jugular vein of rat was exposed and 
cannulated with a polyethylene tube (0.5 mm ID, 1.0 mm OD, Portex Ltd., 
England). For intravenous administration, the right jugular vein of rat was exposed 
and cannulated with two polyethylene tubes (0.4 mm ID, 0.8 mm OD, Portex Ltd., 
England). The polyethylene tubes were then guided subcutaneously out of the body 
at the back of the rat. After the surgery, the rat was allowed to recover over night 
under fasting condition with free access to water. 
For nasal administration, the rat was first anesthetized with an intraperitoneal 
injection of a mixture containing 60 mg/kg ketamine and 6 mg/kg xylazine on the 
day of experiment. Then the rat was placed in supine position and its body 
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temperature was maintained by a heating lamp. The trachea was cannulated from 
an incision made in the neck with a polyethylene tube to aid breathing. A sealed 
polyethylene tube was inserted through the esophagus into the posterior part of the 
nasal cavity to prevent any drainage of the drug solution from the nasal cavity (as 
shown in Figure 4.1). The right jugular vein was exposed and cannulated with a 
polyethylene tube (0.5 mm ID, 1.0 mm OD, Portex Ltd., England). 
2 
4 
Figure 4.1 The experimental set-up for in vivo nasal drug delivery studies in 
the rat model. 1. Nasal cavity; 2. Nasal respiratory region; 3. Esophagus 




4.3.7 Drug administration 
For nasal delivery, meloxicam was dissolved in PBS (pH 7.4) containing 3% 
Tween 80 to reach a final concentration of 3.2 mg/ml. A dose of 1 mg/kg was 
administered to the nasal cavity of rat through the nostril via a polyethylene tube 
(0.4 mm ID, 0.8 mm OD, Portex Ltd., England). Blood samples were withdrawn 
from the jugular vein before and at 2, 4，6, 10，20, 40，60，90 and 120 min 
post-dosing, respectively. 
For oral delivery, the drug solution, which was diluted 10 times with PBS (pH 
7.4) from that prepared for nasal delivery, was given to rat at a dose of 1 mg/kg by 
gastric gavages. Blood samples were withdrawn from the jugular vein before and at 
10，20，30, 45, 60，90 and 120 min post-dosing, respectively. 
For intravenous delivery, the same drug solution as that prepared for oral 
delivery was administered to rat as bolus injection at the dose of 1 mg/kg via one of 
the two cannulated polyethylene tubes. To avoid contamination, blood samples 
were withdrawn from the other cannulated tube before and at 2，4，6，10，20, 40, 60, 
90 and 120 min post-dosing, respectively. 
After each sampling, an equal volume of heparinized normal saline solution 
(20 lU/ml) was immediately injected via jugular vein. The collected blood samples 
were centrifuged at 13,000 rpm for 5 min and the plasma was collected and stored 
at -80°C until analysis. 
4.3.8 Data analysis 
The plasma drug concentration versus time profiles were analyzed with 
WinNonlin Standard 2.1 (Pharsight Corporation, USA). Non-compartmental model 
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was used to estimate the area under the plasma concentration - time curve from 0 
to 2h (AUCo-2h). 
The preliminary correlation between permeabilities of compounds in Calu-3 
cell line model and their nasal bioavailabilities in animal models was evaluated by 
calculating Pearson's correlation coefficient and examining the statistical 
significance of the correlation using SPSS 16.0 (SPSS Inc, USA). 
4.4 Results and discussions 
4.4.1 Validation of the assay method 
HPLC-UV system was employed in all the previous published studies for 
plasma meloxicam concentration determination (Narjes et al., 1996; Busch et al., 
1998; Velpandian et al., 2000; Dasandi et al., 2002; Montoya et al.，2004; 
Marcelin-Jimenez et al., 2005; Bae et al., 2007; Han et al.，2007). Therefore, 
HPLC-UV was also utilized for the current study. For plasma sample preparation, 
most of the reported studies used liquid-liquid extraction method, while protein 
precipitation and solid phase extraction methods were also utilized. During the 
preliminary tests for the plasma sample preparation in the present study, all of the 
above methods were tried. 
4.4.1.1 Specificity 
The representative chromatograms of blank plasma, blank plasma samples 
spiked with meloxicam and a plasma sample obtained from a rat following nasal 
administration of meloxicam (1 mg/kg) are shown in Figure 4.2. Under the assay 
condition, no interference from the endogenous plasma was observed at the 
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retention time of both the analyte and the internal standard. 
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Figure 4.2 HPLC chromatograms of rat plasma samples: (A) Blank plasma; (B) 
Blank plasma spiked with meloxicam at the concentration of 17.57 j^g/ml; (C) 
Plasma sample obtained 20 min after nasal administration of meloxicam (1 mg/kg) 
to a rat. M: meloxicam, IS: internal standard. 
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4.4.1.2 Precision, accuracy and linearity 
The intra-day and inter-day precision and accuracy of the analytical method 
are listed in Table 4.1. The RSD was below 9.46% for both intra-day and inter-day 
assays. The accuracy calculated as the percentage difference of the determined 
concentration from the nominal value was within the range of -3.27% to 5.73%. In 
addition, the calibration curve for meloxicam was linear over the studied 
concentration range with regression coefficients R^>0.9993. 
Table 4.1 Intra-day, inter-day precision and accuracy for the determination of 
meloxicam in rat plasma. 
Nominal Intra-day (n=5) Inter-day (n=5) 
Cone. Precision Accuracy Precision Accuracy 
(l^g/mi) D e t e r m i n e d R S D (%) % D e t e r m i n e d R S D (%) % 
Cone. difference Cone. difference 
(^ig/ml) (l^g/ml) 
0.1757 0.19±0.01 6.67 5.73 0.18±0.02 9.46 0.63 
0.3514 0.34±0.01 3.28 -3.27 0.34±0.02 6.74 -2.32 
3.514 3.64±0.05 1.33 3.45 3.59±0.09 2.59 2.08 
35.14 36.11 ±0.43 1.21 2.75 35.49±0.54 1.55 0.99 
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4.4.1.3 Recovery 
The extraction recoveries of meloxicam from spiked rat plasma at low, 
medium and high concentrations were determined and ranged from 81.85% to 
103.22% (Table 4.2). 
Table 4.2 Extraction recoveries of meloxicam in rat plasma (n=5). 
Sample Cone. (|ig/ml) Recovery (%) 
0.3514 81.85 + 3.32 
3.514 103.22±1.14 
35.14 99.90±2.06 
During the preliminary tests for the plasma sample preparation, various 
methods such as liquid-liquid extraction, protein precipitation and solid phase 
extraction were tried. The protein precipitation method generally led to a fairly low 
extraction recovery of meloxicam (<25%), probably due to the high protein binding 
of meloxicam in plasma (>99% in human plasma) (Davies et al., 1999). For the 
solid phase extraction method (Oasis MAX cartridge, Waters, USA), large 
variation was observed in the preliminary recovery tests of meloxicam (73% to 
98%). The liquid-liquid extraction reported in the published studies employed 
chloroform or diethyl ether as extraction solvent (Velpandian et al., 2000; Han et 
al., 2007; Bae et al., 2007). In the preliminary tests of the present study, chloroform, 
diethyl ether and ethyl acetate were all evaluated for their extraction efficiency. 
The results showed that the highest recovery of meloxicam was obtained with the 
use of ethyl acetate (�90o/o)，whereas lower recoveries of meloxicam were gained 
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when chloroform (<10%) and diethyl ether (-80%) were used. Since meloxicam is 
a weak acid with a pKa of 4.50 (Table 1.1)，HCl was usually added to the plasma 
samples before extraction to increase the extraction efficiency in the previous 
studies (Velpandian et al., 2000; Han et al., 2007; Bae et a l , 2007). In the 
preliminary tests of the present study, 100|il of a series of concentrations of HCl 
and H3PO4 were tried. Generally, HCl was found to cause a more obvious 
precipitation of the protein in plasma than H3PO4, which resulted in a lower 
recovery of meloxicam with the use of HCl as compared to the use of H 3 P O 4 . For 
H3PO4, higher recovery of meloxicam was found to be obtained at the 
concentration of 10% than 5%, and similar recoveries of meloxicam were achieved 
with H3PO4 at the concentrations of 10%, 20% and 30%. 
In view of above, liquid-liquid extraction method using ethyl acetate as 
extraction solvent and 10% H3PO4 as acidifying agent was finalized as the plasma 
sample preparation method in the current study. 
4.4.1.4 Sensitivity 
The limit of quantification (LOQ) for meloxicam was 0.1757|ig/ml and the 
limit of detection (LOD) for meloxicam was 0.08785}ig/ml. Although these values 
are not as low as some literature reported values (Velpandian et a l , 2000; Dasandi 
et a l , 2002)，the current meloxicam plasma assay method is sensitive enough for 
the current pharmacokinetics study. 
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4.4.1.5 Stability 
As shown in Table 4.3, meloxicam was stable for at least three freeze-thaw 
cycles, and was stable in plasma samples at room temperature for 4 hours. In 
addition, meloxicam was also stable in the prepared samples after being placed in 
the auto-sampler at 10°C for 24 hours. 
Table 4.3 Stability of meloxicam in plasma or in prepared samples under various 
conditions (n=3). 
Conditions Nominal Precision Accuracy 
Cone, (^g/ml) D e t e r m i n e d R S D � % ^ 
Cone. (|ag/ml) difference 
Three freeze-thaw 0.3514 0.32±0.02 4.37 -9.32 
cycles 3.514 3.49±0.07 2.11 -0.74 
35.14 34.94 土 0.32 0.91 -0.57 
Room temperature, 0.3514 0.34±0.01 3.14 -3.94 
4 hours 3.514 3.51 ±0.01 0.42 -0.10 
35.14 34.93 ±0.30 0.86 -0.59 
Auto-sampler, 0.3514 0.32 ±0.02 5.59 -7.83 
10°C, 24 hours 3.514 3.47±0.05 1.37 -1.24 
35.14 34.93±0.37 1.04 -0.59 
4.4.2 In vivo absorption studies through the nasal, intravenous and 
oral routes in rat model 
The plasma drug concentration vs. time profile in rats after nasal, oral and 
intravenous administration of 1 mg/kg meloxicam is shown in Figure 4.3. The 
• • • « 
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results demonstrated that meloxicam was quickly absorbed after nasal 
administration (Tmax = 22.86+12.54 min) with high plasma concentrations (Cmax = 
9.51 ±0 .73 }ig/ml), which were comparable with those obtained after intravenous 
administration. On the contrary, meloxicam given via the oral route was absorbed 
slowly, with a plasma concentration of 2.38 ±0 .57 |xg/ml achieved at 2 h. Our 
finding is consistent with the literature (Busch et al., 1998), where Cmax of 
meloxicam following an oral administration in rat (1 mg/kg) was not reached until 
4.4-6.8 h. In addition, the plasma concentrations of meloxicam obtained after oral 
administration were much lower than those obtained after nasal and intravenous 
administration. The AUCo-2h after nasal administration of 1 mg/kg meloxicam was 
971.13 ±90.46|ig.min/ml, which is comparable (p=0.144) with that of intravenous 
administration (1055.11 ±72.68 jxg.min/ml) and much higher than that of oral 
administration (262.59±63.71 ^ig-min/ml) (p<0.0005). 
The in vivo pharmacokinetics investigation lasted only 2 hours in the current 
study, which is mainly due to the limitation of the rat model for nasal drug delivery 
studies. Since the trachea of such rat model was cannulated, it should be kept under 
anaesthetized condition during the experimental period. Therefore, the in vivo 
pharmacokinetics studies cannot last too long. In addition, the objective of the 
current study is to verify that whether nasal delivery of meloxicam can reach faster 
onset of action of the drug as compared to oral administration. Thus, the focus of 
present study is the absorption phase of meloxicam in rat. Moreover, the ti/2 of 
meloxicam in rat is very long (~20h) (Busch et al., 1998; Han et al.，2007)，which 
makes it impossible to obtain the whole pharmacokinetics profile of nasally 
delivered meloxicam in rat. 
Tween 80 (3%) was employed in the meloxicam solution for nasal 
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administration in order to achieve a concentration of 3.2 mg/ml for meloxicam used 
in the current study. It was previously reported that Tween 80 (8%) has no obvious 
nasal ciliotoxicity and irritation in both in situ toad palate model and in vivo rat 
nasal mucosa model (Xie et al., 2006). However, no information on the effect of 
Tween 80 on nasal permeability of a drug is available. Therefore, the current 
findings could not fully exclude the possibility that the rapid nasal absorption and 
high nasal bioavailability of meloxicam in the current study could be resulted from 
the absorption enhancement effect of 3% Tween 80. The role of 3% Tween 80 
needs further verification. 
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Figure 4.3 Plasma drug concentration vs. time profile in rats after nasal, oral and 
intravenous administration of 1 mg/kg meloxicam. The data are expressed as Mean 士 
SD, n=7 or 8. 
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4.4.3 Preliminary correlation between permeabilities of 
compounds in Calu-3 cell line model and their nasal 
bioavailabilities in animal models 
Since in vitro permeabilities of several compounds, including the marker 
compounds and the drug candidates, in the Calu-3 cell line model have been 
studied in the current study, their published in vivo nasal absorption information 
has been obtained to try to provide a preliminary estimation of the in vitro - in vivo 
correlation of the Calu-3 cell line model versus the animal models. 
The nasal bioavailabilities of five compounds, which have been studied in 
Calu-3 cell line model in Chapter Two and Three, are summarized in Table 4.4. It is 
found that the Papp values of these five compounds in Calu-3 cell line model 
correlate well with their nasal bioavailabilities in animal models (Figure 4.4), with 
a Pearson's correlation coefficient (R) of 0.938. In addition, the statistical analysis 
by SPSS indicates that this correlation is highly statistically significant (p=0.006). 
Such preliminary correlation suggests that the Calu-3 cell line model can 
appropriately predict the in vivo nasal absorption of the five studied compounds. 
Since the Papp values of the current five compounds are either in the range of 10'^  
cm/s or 10-7 cm/s, further studies involving drugs with medium lipophilicity (Papp 
in the range of 10"^  cm/s in the Calu-3 cell line model) could further validate the 
capability of the Calu-3 cell line model to predict the in vivo nasal absorption 
situation. 
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Table 4.4 Summary of the apparent permeability coefficients (Papp) of the five compounds 
across Calu-3 cell line model and their nasal bioavailabilities in animal models. 
Compounds Papp in Calu-3 cell line Nasal bioavailability Animal models 
model (x 10"^cm/s) in animal models 
Mannitol 1.14 ± 0.11 0% ^ Rat {in situ model) 
Testosterone 205.01 土9.41 99% (dose: 25 |ig)" Rat 
90% (dose: 50 ^ig) ^ 
Propranolol 227.27±5.50 100%' Human 
Rizatriptan 6.84 ± 0.29 45% d Human 
Meloxicam 188.66 士 16.72 92% ‘ Rat 
a. Gibson et al. (1987); b. Hussain et al. (1984); c. Hussain (1998); d. Chen et al. 
(2005); and e. Calculated as (nasal AUCo-2h)丨(intravenous AUCo-2h) from the data 
in the present study. 
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Figure 4.4 Correlation of apparent permeability coefficients (Papp) of the five 
compounds across Calu-3 cell line model and their nasal bioavailabilities in animal 
models. 
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4.5 Conclusion 
In this chapter, an HPLC-UV analytical method was developed for the 
determination of meloxicam in rat plasma. This method has been fully validated 
with satisfactory accuracy and adequate reproducibility. The pharmacokinetic 
profiles of meloxicam in rats was determined at a dose of 1 mg/kg through the 
nasal route and compared with that obtained through intravenous and oral routes. It 
was found that nasal administration of meloxicam was comparable with its 
intravenous administration, with respect to plasma drug concentration and AUCo-2h-
In addition, nasal absorption of meloxicam was much more rapid with higher 
plasma drug concentration and AUCo-2h than that of oral administration. These data 
confirmed the initial Calu-3 cell line permeation results, which indicated that 
meloxicam may be well absorbed via nasal route of administration. A preliminary 
in vitro — in vivo correlation of the Calu-3 cell line model versus the animal models 
based on data from the current study and the published ones was also estimated. 
The correlation results from five studied compounds suggested that the Calu-3 cell 





Nasal mucosa has been used as a site for systemic drug delivery to achieve 
rapid onset of action of drugs and avoid first-pass metabolism. However, at present 
there is no well validated and readily accessible in vitro biological model that is 
suitable for rapid screening for nasal drug delivery. After a systematic review on 
the possible models for nasal drug permeation studies, Calu-3 cell line model 
appears to be a promising one that might be qualified for the abovementioned 
purpose. Therefore, the current study was designed to (1) develop and preliminarily 
validate the Calu-3 cell line model as an in vitro biological model for nasal drug 
permeation screening; (2) investigate the permeation of selected drug candidates 
using this model, leading to identification of a most promising drug candidate. 
To develop the Calu-3 cell line model, the cells were seeded on the Transwell® 
inserts at a density of 2x10^ cells/well and cultured under an air-interfaced 
condition. The integrity of the Calu-3 cell monolayers was verified by monitoring 
the transepithelial electrical resistance (TEER) and permeabilities of tritiated water 
as well as various transcelluar and paracellular markers. The effect of osmolarity on 
the cell monolayer was also studied. The optimal culture condition for Calu-3 cell 
monolayers for the permeation studies appeared to be between 15 and 21 days of 
culture based on TEER greater than 500 Q-cml The apparent permeability 
coefficients (Papp) of the marker compounds ranged from 1.14 ±0.11 xiQ-^cm/s to 
398.07 + 57.62 xlO'^cm/s, with Papp values of paracellular markers < transcellular 
1 1 4 
Chapter Three 
markers < tritiated water as expected. It was found that hypoosmotic solutions not 
only significantly decreased the TEER of the Calu-3 cell monolayers but also 
significantly enhanced the permeability of the paracellular marker ['"^CJ-Mannitol 
but not the transcellular marker [ H]-Dexamethasone. No significant inter-passage 
variation was found with the cell passage number ranged from 21 to 25. These data 
indicate that the Calu-3 cells grown on Transwell® inserts yielded consistent results 
from standard markers and may be useful as an in vitro model for nasal drug 
permeation screening. 
To further validate the ability of Calu-3 cell line for nasal drug delivery 
screening, four selected drug candidates (i.e. rizatriptan, meloxicam, lomoxicam 
and nebivolol) with potential therapeutic advantage of nasal delivery were 
investigated using the Calu-3 cell line model. It was found that passive diffusion 
was the main transport pathway for rizatriptan, meloxicam and lomoxicam in 
permeating through the Calu-3 cell line model. Their permeabilities were pH 
dependent and hypoosmolarity enhanced the permeability of paracellularly 
transported drug rizatriptan. For nebivolol, it was found to have low solubility, high 
cellular uptake, high cytotoxicity and low permeability in Calu-3 cell line model; 
thus no additional experiment of it was carried out in Calu-3 cell line model. A 
correlation was observed for the permeabilities of drug candidates under different 
pHs between the Calu-3 cell line model and the artificial membrane model (an in 
vitro non-biological model for prediction of passive diffusion of drug permeation 
across biological membranes). These data further confirmed the reliability of the 
Calu-3 cell line model. 
Based on the results of in vitro permeation studies using the Calu-3 cell line 
model, as well as the stability data and the reported pharmacokinetics data in 
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human subjects, meloxicam was selected for further in vivo studies within the 
experimental time of the thesis work. The pharmacokinetic profiles of meloxicam 
in rats was determined at a dose of 1 mg/kg through the nasal route and compared 
with that obtained through intravenous and oral routes. Although the 
pharmacokinetics studies lasted only 2 hours due to the limitation of the rat model 
for nasal drug delivery studies, the data obtained showed important characteristics 
of rapid drug delivery: nasal administration of meloxicam was comparable with its 
intravenous administration, as judged by plasma drug concentration and AUCo-2h. 
In addition, nasal absorption of meloxicam was much more rapid with higher 
plasma drug concentration and AUCo-2h than that of oral administration. A 
preliminary estimation of the in vitro - in vivo correlation of the Calu-3 cell line 
model versus the animal models based on data from the current study and the 
published ones showed that the Calu-3 cell line model can appropriately predict the 
in vivo nasal absorption. 
In conclusion, the results of the present work indicate that the Calu-3 cell line 
model appears to be a suitable in vitro biological model for initial screening of the 
drug candidates for nasal delivery. Although previous published work (Mathias et 
al., 2002) has correlated the data obtained from Calu-3 cell line model with that 
from the in vivo pulmonary absorption in rat, our study is the first one to correlate 
the in vitro Calu-3 cell line model data with that of the in vivo nasal absorption in 
animal models. 




Due to the time restriction, limited work has been completed within the time 
period. Further studies are warranted to improve the validity of the utility of the 
Calu-3 cell line model for nasal drug delivery screening. They are suggested as 
follows: • 
1) In vivo pharmacokinetics studies of the other three drug candidates in 
rat nasal absorption model should be conducted in order to correlate 
with that observed in Calu-3 cell line model. By doing so, we could: 
a) Verify the rank order of the nasal absorption of the four drug 
candidates in vivo so as to ensure the best drug candidate for 
further development. 
b) Further correlate the in vitro findings versus that from in vivo rat 
model in order to further validate Calu-3 cell line model as an 
appropriate in vitro model for nasal drug screening. 
2) Wider variety of drugs with higher molecular weight and different 
lipophilicity can also be chosen for further studies. Permeabilities in the 
Calu-3 cell line model and in vivo nasal bioavailabilities in rat of more 
drugs can be obtained to achieve more precise correlation between the 
in vitro Calu-3 cell line model and the in vivo rat model. More solid 
conclusions could be achieved based on such correlation. 
3) Since the current in vivo rat nasal absorption model can seldom stand 
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longer than 4 h due to the anaesthesia status of the animal, the complete 
nasal pharmacokinetics profiles could barely be obtained in rat model. 
Therefore, \n vivo nasal absorption studies of all the compounds 
suggested in 1) and 2) should be further conducted in bigger animal 
models, such as rabbit and dog, to obtain the full nasal 
pharmacokinetics profiles and bioavailabilities of the drugs. 
4) By achieving 1)，2) and 3), more precise correlations could also be 
obtained between the permeability characteristics of drugs in the in vitro 
Calu-3 cell line model and their in vivo nasal bioavailabilities in various 
animal species. Such correlations will definitely lead to better selection 
of drug candidates for further clinical application. 
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